Questcor Pharmaceuticals (QCOR) Inactive 10-K26 Feb 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2013	Jan. 31, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'QUESTCOR PHARMACEUTICALS INC	'	'
Entity Central Index Key	'0000891288	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	60,583,618	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$1,756,532,593

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$175,840	$80,608
Short-term investments	69,166	74,705
Total cash, cash equivalents and short-term investments	245,006	155,313
Accounts receivable, net of allowances for doubtful accounts of $475 and $0 at December 31, 2013 and December 31, 2012, respectively	87,069	61,417
Inventories, net of allowances of $1,329 and $52 at December 31, 2013 and December 31, 2012, respectively	16,368	9,909
Restricted cash - current portion	25,000	0
Prepaid expenses and other current assets	7,124	4,900
Deferred tax assets	16,209	5,737
Total current assets	396,776	237,276
Property and equipment, net	31,733	2,073
Purchased technology, net	0	1,493
Goodwill	20,464	0
In process R&D asset	191,451	0
Intangibles and other non current assets	30,131	0
Restricted cash	50,000	0
Deposits and other assets	389	70
Deferred tax assets	15,410	11,519
Total assets	736,354	252,431
Current liabilities:	'	'
Accounts payable	14,302	13,069
Accrued compensation	16,489	21,300
Sales-related reserves	35,370	37,376
Accrued royalties	35,163	9,802
Dividend payable	18,093	0
Current portion of contingent consideration	4,238	0
Current portion of in process R&D liability	25,000	0
Income taxes payable	3,693	7,360
Current portion of long-term debt	1,665	0
Other accrued liabilities	7,159	1,492
Total current liabilities	161,172	90,399
Long-term debt, less current portion	13,998	0
Contingent consideration	33,224	0
In process R&D liability	115,066	0
Non current deferred tax liability	10,569	0
Other non current liabilities	2,961	203
Total liabilities	336,990	90,602
Commitments and contingencies (see Note 7)	'	'
Shareholdersâ€™ equity:	'	'
Preferred stock, no par value, 5,334,285 shares authorized; none outstanding	0	0
Common stock, no par value, 105,000,000 shares authorized, 60,137,758 and 58,544,206 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	30,386	15,938
Retained earnings	372,231	145,851
Accumulated other comprehensive income (loss)	-3,253	40
Total shareholdersâ€™ equity	399,364	161,829
Total liabilities and shareholdersâ€™ equity	$736,354	$252,431

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts receivable	$475	$0
Inventory, allowances	$1,329	$52
Common stock, no par value	$0	$0
Common stock, shares authorized	105,000,000	105,000,000
Common stock, shares issued	60,137,758	58,544,206
Common stock, shares outstanding	60,137,758	58,544,206
Preferred stock, no par value	$0	$0
Preferred stock, shares authorized	5,334,285	5,334,285
Preferred stock, shares outstanding	0	0

Consolidated_Statements_Of_Inc

Consolidated Statements Of Income And Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	'	'	'
Pharmaceutical net sales	$761,347	$509,292	$218,169
Contract manufacturing net sales	37,582	0	0
Total net sales	798,929	509,292	218,169
Cost of sales (exclusive of amortization of purchased technology and IPR&D asset)	74,365	28,555	12,459
Gross profit	724,564	480,737	205,710
Operating expenses:	'	'	'
Selling and marketing	152,856	114,139	56,728
General and administrative	56,408	33,596	17,743
Research and development	59,730	34,269	16,778
Depreciation and amortization	4,055	1,219	1,044
Change in fair value of contingent consideration	10,958	0	0
Impairment of goodwill and intangibles	'	'	299
Total operating expenses	284,726	184,210	92,592
Income from operations	439,838	296,527	113,118
Interest and other (expense) income, net	250	703	627
Foreign currency transaction loss	-548	0	0
Income before income taxes	439,540	297,230	113,745
Income tax expense	146,931	99,555	34,154
Net income	292,609	197,675	79,591
Change in unrealized gains or losses on available-for-sale securities, net of related tax effects.	-35	76	-59
Change foreign currency translation adjustments.	-3,258	0	0
Comprehensive Income	$289,316	$197,751	$79,532
Net income per share applicable to common shareholders:	'	'	'
Basic (in dollars per share)	$4.99	$3.28	$1.27
Diluted (in dollars per share)	$4.76	$3.14	$1.21
Shares used in computing net income per share applicable to common shareholders:	'	'	'
Basic (in shares)	58,616	60,243	62,498
Diluted (in shares)	61,447	63,045	66,010
Dividends declared per common share	$1.10	$0.40	$0

Consolidated_Statements_Of_Sha

Consolidated Statements Of Shareholders' Equity (USD $)	Total	Common Stock	Retained Earnings	Accumulated Other Comprehensive Gain (Loss)	Total Shareholdersâ€™ Equity
In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Retained Earnings	Accumulated Other Comprehensive Gain (Loss)	Total Shareholdersâ€™ Equity
Balances at Dec. 31, 2010	'	$74,809	$45,295	$23	$120,127
Balances, shares at Dec. 31, 2010	'	62,418,464	'	'	'
Stock compensation for equity incentives and restricted common stock granted to consultants and employees	'	7,326	0	0	7,326
Stock compensation for equity incentives and restricted common stock granted to consultants and employees, shares	'	31,762	'	'	'
Issuance of common stock pursuant to employee stock purchase plan	'	1,358	0	0	1,358
Issuance of common stock pursuant to employee stock purchase plan, shares	90,650	90,650	'	'	'
Issuance of common stock upon exercise of stock options	'	5,224	0	0	5,224
Issuance of common stock upon exercise of stock options, shares	'	1,991,857	'	'	'
Repurchase of common stock	'	-11,453	0	0	-11,453
Repurchase of common stock, shares	'	-884,300	'	'	'
Cancellation of shares related to tax liability	'	0	0	0	0
Cancellation of shares related to tax liability, shares	'	-2,652	'	'	'
Income tax benefit realized from share-based compensation plans	'	17,712	0	0	17,712
Comprehensive income:	'	'	'	'	'
Net unrealized gain (loss) on investments	-59	0	0	-59	-59
Foreign currency translation adjustment	0	'	'	'	'
Net income	79,591	0	79,591	0	79,591
Balances at Dec. 31, 2011	'	94,976	124,886	-36	219,826
Balances, shares at Dec. 31, 2011	'	63,645,781	'	'	'
Stock compensation for equity incentives and restricted common stock granted to consultants and employees	'	15,792	0	0	15,792
Stock compensation for equity incentives and restricted common stock granted to consultants and employees, shares	'	752,771	'	'	'
Issuance of common stock pursuant to employee stock purchase plan	'	2,660	0	0	2,660
Issuance of common stock pursuant to employee stock purchase plan, shares	92,030	92,030	'	'	'
Issuance of common stock upon exercise of stock options	'	3,675	0	0	3,675
Issuance of common stock upon exercise of stock options, shares	'	819,085	'	'	'
Repurchase of common stock	'	-108,653	-153,177	0	-261,830
Repurchase of common stock, shares	'	-6,759,861	'	'	'
Dividends Paid	'	'	-23,533	'	-23,533
Cancellation of shares related to tax liability	'	0	0	0	0
Cancellation of shares related to tax liability, shares	'	-5,600	'	'	'
Income tax benefit realized from share-based compensation plans	'	7,488	0	0	7,488
Comprehensive income:	'	'	'	'	'
Net unrealized gain (loss) on investments	76	0	0	76	76
Foreign currency translation adjustment	0	'	'	'	'
Net income	197,675	0	197,675	0	197,675
Balances at Dec. 31, 2012	161,829	15,938	145,851	40	161,829
Balances, shares at Dec. 31, 2012	58,544,206	58,544,206	'	'	'
Stock compensation for equity incentives and restricted common stock granted to consultants and employees	'	28,753	0	0	28,753
Stock compensation for equity incentives and restricted common stock granted to consultants and employees, shares	'	789,381	'	'	'
Issuance of common stock pursuant to employee stock purchase plan	'	4,054	0	0	4,054
Issuance of common stock pursuant to employee stock purchase plan, shares	137,472	137,472	'	'	'
Issuance of common stock upon exercise of stock options	'	15,989	0	0	15,989
Issuance of common stock upon exercise of stock options, shares	1,692,920	1,692,920	'	'	'
Repurchase of common stock	'	-53,054	0	0	-53,054
Repurchase of common stock, shares	'	-960,000	'	'	'
Dividends Paid	'	'	-66,229	'	-66,229
Cancellation of shares related to tax liability	'	-4,103	0	0	-4,103
Cancellation of shares related to tax liability, shares	'	-66,221	'	'	'
Income tax benefit realized from share-based compensation plans	'	22,809	0	0	22,809
Comprehensive income:	'	'	'	'	'
Net unrealized gain (loss) on investments	-35	0	0	-35	-35
Foreign currency translation adjustment	-3,258	0	0	-3,258	-3,258
Net income	292,609	0	292,609	0	292,609
Balances at Dec. 31, 2013	$399,364	$30,386	$372,231	($3,253)	$399,364
Balances, shares at Dec. 31, 2013	60,137,758	60,137,758	'	'	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows From Operating Activities	'	'	'
Net income	$292,609	$197,675	$79,591
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Share-based compensation expense	28,753	15,792	7,326
Deferred income taxes	-14,849	241	-4,896
Amortization of investments	412	1,330	1,250
Depreciation and amortization	14,172	1,219	1,044
Impairment of goodwill and intangibles	719	987	299
Loss on disposal of property and equipment	95	72	11
Changes in fair value of contingent consideration	6,429	0	0
Imputed interest for contingent consideration and in-process R&D	4,529	0	0
Other compensation expense	1,892	0	0
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-19,155	-33,616	-16,673
Inventories	4,577	-4,683	-1,500
Prepaid income taxes	0	6,940	-3,408
Prepaid expenses and other current assets	-1,335	-1,509	-1,527
Accounts payable	-589	7,566	1,634
Accrued compensation	-4,811	9,710	7,432
Accrued royalties	25,361	5,463	3,030
Sales-related reserves	-2,006	3,257	12,608
Income taxes payable	-3,667	7,360	0
Other accrued liabilities	3,307	1,317	-504
Other non-current liabilities	1,335	-84	-118
Net cash provided by operating activities	337,778	219,037	85,599
Cash Flows From Investing Activities	'	'	'
Purchase of short-term investments	-120,645	-145,384	-162,301
Proceeds from the sale and maturities of short-term investments	125,737	191,105	112,636
Purchase of property, equipment and leasehold improvements	-3,536	-1,065	-1,823
Restricted cash associated with the acquisition of Synacthen	-75,000	0	0
Acquisition of BioVectra, net of cash acquired	-46,692	0	0
Acquisition of Synacthen	-60,000	0	0
Proceeds from sale of Doral	700	0	0
Changes in deposits and other assets	2,119	-14	9
Net cash (used in) / provided by investing activities	-177,317	44,642	-51,479
Cash Flows From Financing Activities	'	'	'
Repayment of funded long-term debt	-1,219	0	0
Repayment of other long-term debt	-491	0	0
Income tax benefit realized from share-based compensation plans	22,809	7,488	17,712
Issuance of common stock, net	15,940	6,335	6,582
Dividends paid	-48,136	-23,533	0
Repurchase of common stock	-53,054	-261,830	-11,453
Net cash (used in) / provided by financing activities	-64,151	-271,540	12,841
Impact of exchange rate on cash flows	-1,078	0	0
Increase (decrease) in cash and cash equivalents	95,232	-7,861	46,961
Cash and cash equivalents at beginning of year	80,608	88,469	41,508
Cash and cash equivalents at end of year	175,840	80,608	88,469
Supplemental disclosures of Cash Flow Information:	'	'	'
Cash paid for interest	704	23	16
Cash paid for income taxes	141,515	77,556	25,278
Dividend payable	18,093	11,691	0
Supplemental disclosure of non-cash investing and financing activities:	'	'	'
Capital lease obligation	0	31	34
Incremental fair value of assets acquired, net	80,698	'	'
Incremental fair value of assets acquired, net	-30,383	'	'
Fair value of assets acquired	50,315	'	'
Foreign currency transaction loss	488	'	'
Total cash paid for acquisition of BioVectra	$50,803	'	'

Organization_And_Summary_Of_Si

Organization And Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	Organization and Summary of Significant Accounting Policies
	The Company
	Questcor is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. We also supply specialty contract manufacturing services to the global pharmaceutical and biotechnology industry through our wholly-owned subsidiary, BioVectra Inc. Our primary product is H.P. Acthar® Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of 19 indications. Of these 19 FDA approved indications, for the year ended December 31, 2013, we generated substantially all of our net sales from the following indications:

	•	Nephrotic Syndrome (NS): Acthar is indicated “to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.” According to the National Kidney Foundation, nephrotic syndrome can result from several idiopathic type kidney disorders, including idiopathic membranous nephropathy, focal segmental glomerulosclerosis, IgA nephropathy and minimal change disease. Nephrotic syndrome can also occur due to lupus erythematosus. In this Form 10-K, the terms “nephrotic syndrome” and “NS” refer only to the proteinuria in nephrotic syndrome conditions that are covered by the Acthar label of approved indications.

	•	Rheumatology Related Conditions: Acthar is approved for the following rheumatology related conditions: (i) Collagen Diseases: Acthar is indicated "during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, systemic dermatomyositis (polymyositis)" and (ii) Rheumatic Disorders: Acthar is indicated as "adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), and Ankylosing spondylitis."

	•	Multiple Sclerosis (MS): Acthar is indicated “for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.”

	•	Infantile Spasms (IS): Acthar is indicated “as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age.”
	We continue to explore additional markets for other on-label indications. For example, in 2013 we initiated a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis. In addition, we are exploring the possibility of pursuing FDA approval for indications not currently on the Acthar label that are related to the treatment of other serious, difficult-to-treat autoimmune and inflammatory disorders having high unmet medical need.
	In order to improve outcomes for patients with difficult-to-treat autoimmune and inflammatory disorders, we are expanding our research to better understand the mechanism(s) of action of Acthar as well as the pharmacology of Acthar across and within each indication. We are also conducting studies to expand our understanding of why Acthar acts differently than steroids and potentially other melanocortin peptides.
	Basis of Presentation
	The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
	The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income in shareholders' equity. Foreign currency transaction gains and losses are included in the results of operations in our Consolidated Statements of Income and Comprehensive Income.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP, requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Our significant estimates include our estimates for sales-related reserves, valuation and impairment of intangibles and goodwill, deferred tax assets and tax liabilities, share-based compensation and estimating the fair value of our contingent consideration in conjunction with the acquisition of both BioVectra and Synacthen, among others.
	Reclassifications
	Certain comparative prior year amounts in the Consolidated Financial Statements and accompanying notes have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net income.
	Fair Value of Financial Instruments
	Our financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, dividends payable, accrued liabilities, current and long-term debt and derivatives (primarily associated with the contingent consideration in conjunction with the acquisition of Synacthen). We believe that the fair value of these financial instruments approximate the reported carrying amounts.
	Cash Equivalents and Short-Term Investments
	We consider highly liquid investments with maturities from the date of purchase of three months or less to be cash equivalents. We classify available-for-sale debt instruments with maturities at the date of purchase greater than three months as short-term investments.
	We carry available-for-sale securities at fair value, with the unrealized gains and losses, if any, reported in a separate component of shareholders’ equity. If we deem the decline in value to be other-than-temporary and we intend to sell such securities before their full cost can be recovered, we write down such securities to fair value and we charge the loss to net realized losses on investments. We use significant judgment in the determination of when an other-than-temporary decline in value has occurred. We evaluate our investment securities for other-than-temporary declines based on quantitative and qualitative factors. As of December 31, 2013 none of our investments had an other-than-temporary decline in valuation, and no other-than-temporary losses were recognized during the years ended December 31, 2013, 2012 and 2011. We base the cost of securities sold on the specific identification method. We include realized gains and losses, if any, in the accompanying Consolidated Statements of Income and Comprehensive Income, in Interest and other (expense) income, net.
	Concentration of Risk
	Financial instruments that subject us to a significant concentration of credit risk principally consist of cash and cash equivalents, short-term investments and accounts receivable. We invest our cash in high credit quality government and corporate debt instruments and believe the financial risks associated with these instruments are minimal.
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. Beginning January 1, 2013, all of our non-interest bearing cash balances were insured up to $250,000 per depositor at each financial institution.
	We extend credit to our specialty distributor, which accounts for approximately 95% of our gross product sales and 92% of our accounts receivable. We have not experienced material credit losses on our customer accounts.
	The relative share of our accounts receivable and gross product sales are as follows:



			Years Ended
			December 31,
	% of Accounts Receivable		2013			2012
	Specialty distributor		92	%		100	%
	Other customers		8	%		—	%
			100	%		100	%



			Years Ended December 31,
	% of Gross Product Sales		2013			2012			2011
	Specialty distributor		95	%		100	%		100	%
	Other customers		5	%		—	%		—	%
			100	%		100	%		100	%
	Inventories
	We state inventories, net of allowances, at the lower of cost or market value. For our Acthar product, cost is determined by the first-in, first-out method. For our production materials and supplies, work-in-process and finished goods at our contract manufacturer, cost is determined on an average cost basis.
	We review inventory periodically for slow-moving or obsolete status. We adjust our inventory if we do not expect to recover the cost of inventory. We would record a reserve to adjust inventory to its net realizable value when any of the following occur: (i) a product is close to expiration and we do not expect it to be sold, (ii) a product has reached its expiration date or (iii) we do not expect a product to be saleable. In determining the reserves for these products, we consider factors such as the amount of inventory on hand and its remaining shelf life, and current and expected market conditions, including management forecasts and levels of competition. We have evaluated the current level of inventory considering historical trends and other factors, and based on our evaluation, have recorded adjustments to reflect inventory at its net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to assess the future demand for our products in order to categorize the status of such inventory items as slow-moving, obsolete or in excess-of-need. These future estimates are subject to the ongoing accuracy of our forecasts of market conditions, industry trends, competition and other factors. Differences between our estimated reserves and actual inventory adjustments have been immaterial, and we account for such adjustments in the current period as a change in estimate.
	Property and Equipment
	We record property and equipment at cost. We depreciate equipment and furniture using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. We amortize equipment acquired under capital leases over the estimated useful life of the assets and include such amortization in depreciation expense.
	Goodwill and Intangible Assets
	We determine the estimated fair values of goodwill and intangible assets with definite and/or indefinite lives based on valuations performed at the time of their acquisition in accordance with FASB ASC 350. Such valuations utilize forecasted financial information. In addition, certain amounts paid to third parties, such as our In Process R&D asset related to the acquisition of Synacthen, are capitalized and included in intangible assets on the accompanying consolidated balance sheets.
	Goodwill and indefinite-lived intangibles are tested for impairment annually and in interim periods if certain events occur indicating the fair value may be below its carrying value using a two-step process. The first step is to identify a potential impairment, and the second step measures the amount of the impairment loss, if any. Goodwill is impaired if the carrying amount of a reporting unit’s goodwill exceeds its estimated fair value. We performed our annual goodwill and indefinite-lived impairment assessment as of December 31, 2013, noting no impairment.
	Definite lived intangibles are amortized on an accelerated or straight-line basis over their estimated useful life. This determination is made based on the specific asset and the timing of recoverability from expected future cash flows.
	We review the carrying value of our definite-lived intangibles and long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable. These assets are impaired when undiscounted expected future cash flows are less than the carrying value. Our judgments related to the expected useful lives of definite-lived intangibles and long-lived assets and our ability to realize undiscounted cash flows in excess of the carrying amounts of such assets are affected by factors such as ongoing maintenance and improvements of the assets, changes in economic conditions, our ability to successfully launch products, and changes in operating performance. In addition, we regularly evaluate our long-lived assets and may accelerate depreciation over the revised useful life if the asset has limited future value. During the years ended December 31, 2013, 2012 and 2011, we recorded impairment charges for purchased technology and goodwill of $0.7 million, $1.0 million and $0.3 million, respectively.
	As this process involves management making certain estimates and because these estimates form the basis of the determination of whether or not an impairment charge should be recorded, these estimates are considered to be critical accounting estimates. We will continue to assess the carrying value of our goodwill, intangible assets and long-lived assets in accordance with applicable accounting guidance.
	Income Taxes
	We account for income taxes under the provisions of Accounting Standards Codification 740, “Income Taxes”, or ASC 740. We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.
	As part of the process of preparing our consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating our tax exposure under the most current tax laws and assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets.
	We regularly assess the likelihood that we will be able to recover our deferred tax assets, which is ultimately dependent on us generating future taxable income. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. If it is not considered “more likely than not” that we will recover our deferred tax assets, we will increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. Changes in the valuation allowance based on our assessment will result in an income tax benefit if the valuation allowance is decreased and an income tax expense if the valuation allowance is increased.
	As of December 31, 2013, we have recorded a liability for unrecognized tax benefits of $1.3 million related to various federal and state income tax matters. Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of tax expense. As of December 31, 2013 and 2012, our accrual for interest and penalties on any unrecognized tax benefits was $78,000 and $106,000, respectively. We expect unrecognized tax benefits to decrease by approximately $0.5 million over the next 12 months as a result of the settlement of an IRS examination.
Revenue Recognition
We recognize revenue in accordance with Accounting Standards Codification 605, “Revenue Recognition-Products,” or ASC 605. Pursuant to ASC 605, we recognize revenue when we have persuasive evidence that an arrangement, agreement or contract exists, when each of the following three criteria are satisfied: (i) title for our product and risk of loss have passed to our customer, (ii) the price we charge for our product is fixed or is readily determinable, and (iii) we are reasonably assured of collecting the amounts owed under the resulting receivable. We do not require collateral from our customers.
In the U.S., our exclusive customer for Acthar is a specialty distributor. For our sales to this specialty distributor, a sale of Acthar occurs when the specialty distributor accepts a shipment of Acthar based on its order of Acthar from our exclusive agent for commercial shipment of Acthar to the specialty distributor. We sell Acthar at a discount from our list price to the specialty distributor, which then sells Acthar primarily to approximately 12 specialty pharmacy companies and many hospitals.
We provide free vials of Acthar, to support a patient assistance program administered by a third party administrator. We do not recognize any revenue or net sales from this program.
Separately, we make charitable contributions, in dollars, to independent third-party charitable organizations which administer co-pay assistance programs.
International sales of our products are immaterial.

Net Sales
The following table sets forth our net sales for the years ended December 31, 2013, 2012 and 2011, respectively (in thousands):



		Years Ended December 31,
		2013				2012				2011
Total pharmaceutical gross sales		$	825,710			$	582,097			$	268,827

Sales reserves		64,363				72,805				50,658

Total pharmaceutical net sales		761,347				509,292				218,169

Total contract manufacturing net sales		37,582				—				—

Total net sales		$	798,929			$	509,292			$	218,169

We record net sales after establishing reserves for the following:

i.	Medicaid rebates;

ii.	TRICARE retail program rebates;

iii.	Medicare Part D Coverage Gap Discount Program rebates;

iv.	Chargebacks due to other government programs;

v.	Questcor-sponsored co-pay assistance programs;

vi.	Exchanges, which have historically been immaterial; and

vii.	Other deductions such as payment discounts.
We currently provide our products to Medicaid participants under an agreement with CMS. Under this agreement, states are eligible to receive rebates from us for Medicaid patients in accordance with CMS regulations. States have historically provided us with rebate invoices for their Medicaid Fee for Service reimbursements between 60 and 90 days after the end of the calendar quarter in which our products were provided. Certain states are taking longer to submit complete rebate invoices for the Medicaid Managed Care utilization that became rebate eligible on March 23, 2010, as a result of the enactment of the Health Care Reform Acts.
Significant judgment is inherent in the selection of assumptions and the interpretation of historical experience as well as the identification of external and internal factors affecting the determination of our reserves for Medicaid rebates and other government program rebates and chargebacks. We believe that the assumptions used to determine these sales reserves are reasonable considering known facts and circumstances. However, our Medicaid rebates and other government program rebates and chargebacks could materially differ from our reserve amounts because of unanticipated changes in prescription trends or patterns in the states' submissions of Medicaid claims, adjustments to the amount of product in the distribution channel, or if our estimates of the number of Medicaid patients with IS, MS, NS and rheumatology related-conditions are incorrect. We have greater visibility on the future submission of Medicaid claims and the amount of product in the distribution channel for Acthar distributed to certain specialty pharmacies than we have with respect to Acthar distributed through other specialty pharmacies. If actual Medicaid rebates, or other government program rebates and chargebacks are materially different from our estimates, we would account for such differences as a change in estimate in the period in which they become known. If actual future payments for such reserves exceed the estimates we made at the time of sale, our consolidated financial position, results of operations and cash flows may be negatively impacted.
The following table summarizes the activity in the account for sales-related reserves for Medicaid rebates (in thousands):


		Years Ended December 31,
		2013				2012				2011
Balance at January 1		$	33,921			$	29,874			$	17,384

Actual Medicaid rebate payments for sales made in prior year		(22,891		)		(18,449		)		(9,104		)
Actual Medicaid rebate payments for sales made in current year		(19,333		)		(35,709		)		(24,887		)
Current Medicaid rebate provision for sales made in prior year		11,500				1,153				8

Current Medicaid rebate provision for sales made in current year		27,784				57,052				46,473

Balance at December 31		$	30,981			$	33,921			$	29,874

Total Sales-related Reserves
At December 31, 2013 and 2012 sales-related reserves included in the accompanying Consolidated Balance Sheets were as follows (in thousands):



		Years Ended December 31,
		2013				2012
Medicaid rebates		$	30,981			$	33,921

Other rebates, chargebacks and discounts		4,389				3,455

Total		$	35,370			$	37,376

Product Exchanges
Acthar has a shelf life of 18 months from the date of manufacture. We authorize Acthar exchanges for expiring and expired product in accordance with our stated return policy, which allows the specialty distributor we work with to return product within one month of its expiration date and for a period up to three months after such product has reached its expiration date. Product exchanges have been insignificant since we began utilizing the services of a specialty distributor to distribute Acthar.
Share-Based Compensation
We recognize compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at grant date using an option pricing model and the portion that is ultimately expected to vest is recognized as compensation cost over either (1) the requisite service period or (2) the performance period.
Since share-based compensation is recognized only for those awards that are ultimately expected to vest, we have applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised, if necessary, in future periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards. The determination of fair value using the Black-Scholes option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. We estimate the expected term based on the contractual term of the awards and employees' exercise and expected post-vesting termination behavior.
We use the intrinsic method to account for restricted stock awards. The restricted stock awards are valued based on the closing stock price on the date of grant and amortized ratably over the life of the award.
Additionally, we are required to disclose in our consolidated statements of cash flows the income tax effects resulting from share-based payment arrangements. We adopted the simplified method to calculate the beginning balance of the additional paid-in capital, or APIC, pool of excess tax benefits, and to determine the subsequent effect on the APIC pool and consolidated statements of cash flows of the tax effects of employee share-based compensation awards.
At December 31, 2013, there was $25.8 million of total unrecognized compensation cost related to unvested restricted stock awards and restricted stock units and $20.4 million of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.2 years.
Our share-based compensation plans are discussed further in Note 6. Preferred Stock and Shareholders’ Equity.
Stock Repurchases
We account for common stock repurchases by charging the cost of shares acquired to the common stock account in the Consolidated Statements of Shareholders’ Equity.
Net Income Per Share
Basic net income per share applicable to common shareholders is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalents shares, such as stock options and restricted stock outstanding during the period. Diluted earnings for our common shareholders per common stock considers the impact of potentially dilutive securities and excludes the impact of potential common shares related to our stock options and restricted stock in periods in which the option exercise or conversion price is greater than the average market price of our common stock during the period.
The following table presents the amounts used in computing basic and diluted net income per share applicable to common shareholders for the years ended December 31, 2013, 2012 and 2011 and the effect of dilutive potential common shares on the number of shares used in computing dilutive net income per share applicable to common shareholders. Diluted potential common shares resulting from the assumed exercise of outstanding stock options and restricted stock are determined based on the treasury stock method (in thousands, except per share amounts).



		Years Ended December 31,
		2013				2012				2011
Net income applicable to common shareholders		$	292,609			$	197,675			$	79,591

Shares used in computing net income per share applicable to common shareholders:
Basic		58,616				60,243				62,498

Effect of dilutive potential common shares:
Stock options		2,375				2,744				3,497

Restricted stock		456				58				15

Diluted		61,447				63,045				66,010

Net income per share applicable to common shareholders:
Basic		$	4.99			$	3.28			$	1.27

Diluted		$	4.76			$	3.14			$	1.21

The following table presents the amounts excluded from the computation of diluted net income per share applicable to common shareholders for the years ended December 31, 2013, 2012 and 2011, as the inclusion of these securities would have been anti-dilutive (in thousands):


		Years Ended December 31,
		2013			2012			2011
Stock options		448			1,189			82

Restricted stock awards		30			—			—

Basic and diluted net income per share also takes into consideration the two-class method. Under the two-class method, undistributed net income is allocated to common stock and unvested participating securities based on their respective rights to share in dividends. We have determined that restricted stock awards represent participating securities and, therefore, require the use of the two-class method for the calculation of basic and diluted earnings per share. During the year ended December 31, 2013, we issued restricted stock units to certain employees under our 2006 Equity Incentive Plan. Because the holders of the restricted stock units will only receive dividends on restricted stock units that have vested prior to the Company declaring dividends, we have determined that the restricted stock units are non-participating securities and will not be included in our two-class method calculation.
The following table sets forth the calculation of unallocated undistributed earnings, both basic and diluted, using the two-class method for amounts attributable to our common stock and our restricted stock awards (in thousands):


		Years Ended December 31,
		2013				2012				2011
Net income applicable to common shareholders		$	292,609			$	197,675			$	79,591

Less: Dividends		66,229				23,682				—

Undistributed earnings		$	226,380			$	173,993			$	79,591


Common stock undistributed earnings		$	221,278			$	173,325			$	79,591

Unvested restricted stock award undistributed earnings		5,102				668				—

Total undistributed earnings		$	226,380			$	173,993			$	79,591

Segment Information
We have historically operated in one business segment. On January 18, 2013, we acquired 100% of the issued and outstanding shares of BioVectra Inc. We now manage our operations through two operating segments that are defined by our separate companies - Questcor Pharmaceuticals, Inc. and BioVectra. Each segment is operated as an independent business under its own management team, and has responsibility for its commercial activities, operations, and research and development activities related to its products. We intend to have BioVectra continue to operate independently under its existing management team for the foreseeable future.
Questcor Pharmaceuticals is headquartered in Anaheim, California, and is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor Pharmaceuticals' primary product is Acthar. Questcor Pharmaceuticals currently generates substantially all of its net sales from the use of Acthar in connection with the following: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of certain rheumatology-related conditions, and the treatment of infantile spasms in infants and children under two years of age.
BioVectra is located in Prince Edward Island, Canada, operating from three facilities. BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry. BioVectra manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents, and is our manufacturing partner for the API in our H.P. Acthar® Gel (repository corticotropin injection). BioVectra is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules.
Segment results for net sales are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net income, which includes the negative impact of purchase price adjustments related to our January 18, 2013 acquisition of BioVectra, is the primary responsibility of segment operating management and therefore all activities remain in the segment in which incurred for performance assessment by our chief operating decision maker.
Financial Information by Operating Segment. For the years ended December 31, 2013, 2012 and 2011, information regarding our net sales and net income for our operating segments is as follows (in millions):


	Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
Net Sales
For the year ended December 31, 2013	$	761,347		$	39,944		$	(2,362	)	$	798,929

For the year ended December 31, 2012	$	509,292		$	—		$	—		$	509,292

For the year ended December 31, 2011	$	218,169		$	—		$	—		$	218,169

Net Income
For the year ended December 31, 2013	$	293,999		$	(158	)	$	(1,232	)	$	292,609

For the year ended December 31, 2012	$	197,675		$	—		$	—		$	197,675

For the year ended December 31, 2011	$	79,591		$	—		$	—		$	79,591

As of December 31, 2013, 2012 and 2011, information regarding total assets for our operating segments is as follows (in millions):


	Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
Total Assets
31-Dec-13	$	711,507		$	108,510		$	(83,663	)	$	736,354

31-Dec-12	$	252,431		$	—		$	—		$	252,431

31-Dec-11	$	275,808		$	—		$	—		$	275,808

As of December 31, 2013, 2012 and 2011, information regarding capital expenditures for our operating segments is as follows (in millions):


	Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
Capital expenditures
31-Dec-13	$	1,100		$	2,426		$	10		$	3,536

31-Dec-12	$	1,065		$	—		$	—		$	1,065

31-Dec-11	$	1,823		$	—		$	—		$	1,823

Geographic Information: The Company's geographic information for net sales to unaffiliated customers is shown below. The basis for determining net sales is the geographic location of the customer (in thousands):


	December 31,
	2013			2012			2011
Net Sales
North America (1)	$	778,859		$	509,292		$	218,169

Europe	13,780			—			—

Asia	6,248			—			—

Other	42			—			—

Total net sales	$	798,929		$	509,292		$	218,169

(1) Predominately located in the United States and Canada.
Subsequent Events
We evaluated subsequent events that have occurred after December 31, 2013, and through the issuance date, and determined that there were no events or transactions occurring during this reporting period that require recognition or disclosure in our consolidated financial statements.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. We did not adopt any new accounting pronouncements during the year ended December 31, 2013 that had a material effect on our financial position or results of operations.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	Acquisition of Synacthen
	On June 11, 2013, the Effective Date, we acquired from Novartis AG and Novartis Pharma AG, collectively Novartis, a license to develop, market, manufacture, distribute, sell and commercialize Synacthen and Synacthen Depot for all uses in humans in the United States. Subject to certain conditions and limitations in the License Agreement, the license is exclusive, perpetual and irrevocable. Synacthen is a synthetic melanocortin agonist approved in various countries outside of the United States for certain autoimmune and inflammatory conditions. We have implemented a research and development program for Synacthen and intend to seek FDA approval. Synacthen has never been developed or approved for patients in the United States.
	Subject to certain closing conditions, we also will acquire from Novartis a license and certain assets to develop, market, manufacture, distribute, sell and commercialize Synacthen and Synacthen Depot in certain countries outside the U.S. for all uses in humans. Subject to certain conditions and limitations, these rights and assets are exclusive, perpetual and irrevocable.
	Under the terms of the transaction agreements, we paid Novartis an upfront consideration of $60 million. We will also be making annual cash payments of $25 million on each of the first, second and third anniversaries of the Effective Date, a potential additional annual cash payment on each anniversary subsequent to the third anniversary until we obtain the first approval of the FDA related to the products, or the FDA Approval, and a milestone payment upon our receipt of the FDA Approval. If we successfully obtain the FDA Approval, we will pay an annual royalty to Novartis based on a percentage of the net sales of the product in the U.S. market until the maximum payment is met. The first three annual payments aggregating to $75 million are secured by a letter of credit and classified as restricted cash on the Condensed Consolidated Balance Sheets. In no event will the total payments related to this transaction exceed $300 million.
	As of December 31, 2013, we recorded an asset (because it was determined that the intangible asset has alternative future use) related to the acquisition of Synacthen of $191.5 million and a corresponding liability of $140.1 million. The asset and liability (which was determined to be a derivative) were originally valued using a weighted discounted probability model. The asset is considered to be definite-lived and is amortized over its useful life to research and development expense. The liability is reviewed each reporting period for any changes in the probability assumptions and for changes due to the passage of time.
	Acquisition of BioVectra Inc.
	On January 18, 2013, we completed our acquisition of BioVectra Inc. BioVectra is located in Prince Edward Island, Canada, and is a supplier of specialty contract manufacturing services to the global pharmaceutical and biotechnology industry. BioVectra manufactures active pharmaceutical ingredients, or API, chemical intermediates, and bioprocessing reagents. BioVectra has been our manufacturing partner for the API in Acthar since April, 2003.
	We acquired 100% of the issued and outstanding shares of BioVectra for $50.3 million utilizing cash on hand. The former shareholders of BioVectra could receive additional cash consideration of up to C$50.0 million based on BioVectra's financial results over the next three years. Contingent consideration in conjunction with the acquisition of BioVectra of $30.4 million was recorded on our Consolidated Balance Sheet at the acquisition date. Any differences between our estimate and actual payments or subsequent adjustments are recorded in operating expenses. In 2013, BioVectra met its performance milestones for the year and earned an additional C$5.0 million in consideration.
	As of December 31, 2013, due to the financial performance in 2013 and the updated financial projections for 2014 and 2015 for BioVectra, we recorded a change in fair value associated with the contingent consideration. As of December 31, 2013, the estimated value of the contingent consideration of $37.5 million has been recorded as a liability in our condensed consolidated balance sheets ($4.2 million has been recorded as the current portion of the contingent consideration).
	For the year ended December 31, 2013, we recorded $0.3 million of acquisition-related expenses associated with the BioVectra acquisition within general and administrative expenses in our Condensed Consolidated Statements of Income and Comprehensive Income.
	The acquisition was recorded by allocating the estimated value of consideration paid by us for the BioVectra acquisition to the assets acquired including intangible assets, and liabilities assumed, based on their estimated fair values at the acquisition date in accordance with the acquisition method of accounting. After assigning the fair value of all assets and liabilities identified, including all identified intangibles, there was excess purchase consideration transferred over the fair value of net assets acquired, resulting in the recognition of goodwill. The transaction resulted in goodwill due to assembled workforce, manufacturing exclusivity, and other synergies. Goodwill recorded in the transaction is not deductible for tax purposes. We have finalized the amounts shown below.
	The following table reflects the fair value of consideration transferred at the acquisition date (in thousands):



	Allocation of Purchase Price:
	Current assets excluding inventory	$	11,691

	Inventory	11,774

	Property and equipment	35,221

	Other non-current assets	1,708

	Current deferred tax asset	141

	Intangibles	35,581

	Goodwill	21,914

	Current liabilities	(6,451		)
	Non-current liabilities, excluding long-term debt	(1,994		)
	Non-current deferred tax liability	(12,012		)
	Long-term debt	(16,875		)
	Total net assets acquired	$	80,698


	Cash consideration paid to BioVectra shareholders	$	50,315

	Estimated fair value of contingent consideration	30,383

	Total purchase consideration	$	80,698

	The following unaudited pro forma financial information for the years ended December 31, 2013 and 2012 presents the combined results of operations of Questcor and the BioVectra acquisition described above, as if the acquisition had occurred as of January 1 of the year prior to acquisition. The unaudited pro forma financial information is not intended to represent or be indicative of the Company's consolidated results of operations or financial condition that would have been reported had this acquisition been completed as of the beginning of the periods presented and should not be taken as indicative of the Company's future consolidated results of operations or financial condition. Pro forma adjustments are tax-effected at the applicable statutory tax rates.


		Year Ended December 31,
		2013			2012
	Net sales	$	800,788		$	537,511

	Net income	$	301,837		$	193,389

Balance_Sheet_Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Balance Sheet Details	'
	Balance Sheet Details
	Inventories
	We state inventories, net of allowances, at the lower of cost (first-in, first-to-expire) or market. For our production materials and supplies, work-in-process and finished goods at our contract manufacturer, cost is determined on an average cost basis. Inventories, net of allowances, at December 31, 2013 and 2012 consist of the following (in thousands):



			Years Ended December 31,
			2013			2012
	Raw materials		$	9,835		$	9,271

	Work-in-process		2,194			—

	Intermediates		1,572			—

	Finished goods		4,096			690

			17,697			9,961

	Less: Reserve for obsolescence		(1,329		)	(52		)
			$	16,368		$	9,909

	Included in inventories at December 31, 2013 is $6.7 million held at BioVectra, in Canada.
	Property and Equipment
	Equipment, building, land and leasehold improvements and related accumulated depreciation and amortization are as follows (in thousands):



			Years Ended December 31,
			2013			2012
	Equipment (including manufacturing, laboratory and office)		$	26,237		$	3,466

	Building		12,015			—

	Land and land improvements		406			—

	Leasehold improvements		1,446			1,349

			40,104			4,815

	Less accumulated depreciation and amortization		(8,371		)	(2,742		)
			$	31,733		$	2,073

	Total depreciation and amortization expense amounted to $5.9 million, $0.9 million and $0.7 million for the years ended December 31, 2013, 2012 and 2011 respectively. The increase in depreciation and amortization expense was due to the increase in property, plant and equipment as a result of our acquisition of BioVectra on January 18, 2013. We depreciate our property and equipment and amortize our leasehold improvements using the straight-line method of depreciation. Included in property, plant and equipment at December 31, 2013 is $29.4 million held at BioVectra, in Canada. Included in depreciation and amortization expense for the year ended December 31, 2013 is $5.1 million for assets held at BioVectra, in Canada.
	*Long-term Debt*
	Funded long-term debt
	Our subsidiary, BioVectra, has a supply agreement with a customer to supply a pharmaceutical product for a period of 10 years ending in June 2023. Per the supply agreement, BioVectra financed and constructed a facility for the manufacture of the pharmaceutical product to be supplied under the agreement. BioVectra entered into a term loan agreement to finance C$14.8 million of the construction costs of the facility. The term loan has an interest rate of 4%, is due in full by February 2022 and is secured by certain of our BioVectra assets. Under the supply agreement, the customer agreed to reimburse BioVectra (such reimbursement is recorded to net sales) for the quarterly financing payments of C$450,743 during the term of the loan.


		December 31, 2013
	4% Term Loan, due February 2022, payable in quarterly installments of C$450,743 including principal and interest	$	12,090

	Less: Current Portion	1,221

	Funded long-term debt, less current portion	$	10,869

	Long-term debt
	Our subsidiary, BioVectra, has a 2.85% term loan. The loan is payable monthly and is due April 2016. The loan is secured with BioVectra accounts receivable and inventory.


		December 31, 2013
	2.85% Term Loan, due April 2016, payable in monthly installments of C$48,170 including principal and interest	$	3,573

	Less: Current Portion	444

Long-term debt, less current portion	$	3,129

Debt maturity schedule


2014	$	1,665

2015	1,727

2016	3,994

2017	1,375

2018	1,431

Thereafter	5,471

Total	$	15,663

ShortTerm_Investments_And_Fair

Short-Term Investments And Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Short-Term Investments And Fair Value Measurements [Abstract]	'
Short-Term Investments and Fair Value Measurements	'
	Short-Term Investments and Fair Value Measurements
	A summary of cash equivalents and short-term investments, classified as available-for-sale, and carried at fair value is as follows (in thousands):


	December 31, 2013		Amortized				Gross		Gross			Estimated
			Cost				Unrealized		Unrealized			Fair
							Gain		(Loss)			Value
	Cash equivalents		$	13,351			$	—	$	—		$	13,351

	Short-term investments:
	Corporate bonds		$	45,190			$	11	$	(14	)	$	45,187

	U.S. Government-sponsored enterprises		14,539				3		(4		)	14,538

	Municipal bonds		9,438				4		(1		)	9,441

			$	69,167			$	18	$	(19	)	$	69,166

	December 31, 2012
	Cash equivalents		$	7,740			$	—	$	—		$	7,740

	Short-term investments:
	Certificates of deposit		$	720			$	2	$	—		$	722

	Corporate Bonds		47,857				29		(8		)	47,878

	Government-sponsored enterprises		24,699				13		—			24,712

	Municipal bonds		1,395				1		(3		)	1,393

			$	74,671			$	45	$	(11	)	$	74,705

	Cash proceeds from the sale of our short-term investments are generally reinvested; however, during 2013, we used some of the proceeds to acquire both BioVectra and Synacthen. Cash proceeds are being reinvested since the acquisitions.
	The amortized cost and fair value of available-for-sale securities at December 31, 2013, by contractual maturity, are as follows (in thousands):


			Amortized				Estimated Fair
			Cost				Value
	Due in one year or less		$	31,717			$	31,721

	Due after one through two years		37,450				37,445

	Total available-for-sale securities		$	69,167			$	69,166

	As of December 31, 2013, the average contractual maturity of our short-term investments was approximately 13 months.
	As of December 31, 2013, we had the following available-for-sale securities that were in an unrealized loss position but were not deemed to be other-than-temporarily impaired (in thousands):


			Less Than 12 Months						12 Months or Greater
			Gross Unrealized Losses				Estimated Fair Value		Gross Unrealized Losses			Estimated Fair Value
	Corporate bonds		$	(4	)		$	9,809	$	(10	)	$	8,932

	U.S. Government-sponsored enterprises		—				—		(4		)	9,033

	Municipal bonds		—				1,336		(1		)	1,473

	Total		$	(4	)		$	11,145	$	(15	)	$	19,438

	The gross unrealized losses reported above for December 31, 2013 were caused by general fluctuations in market interest rates from the respective purchase date of these securities through December 31, 2013. No significant facts or circumstances have occurred to indicate that these unrealized losses are related to any deterioration in the creditworthiness of the issuers of the marketable securities we own. Based on our review of these securities, including our assessment of the duration and severity of the related unrealized losses, we have not recorded any other-than-temporary impairments on these investments.
	Fair Value Measurements
	We account for fair value measurements under Accounting Standards Codification 820 “Fair Value Measurements and Disclosures,” or ASC 820, which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

	•	Level 1 – Quoted prices in active markets for identical assets or liabilities.

•	Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
We have segregated all assets and liabilities measured at fair value on a recurring basis (at least annually) into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. As of December 31, 2013 and 2012, assets and liabilities measured at fair value on a recurring basis are summarized below (in thousands):



			Basis of Fair Value Measurements
			Balance at
Balance Sheet Classification			December 31,				Level 1		Level 2			Level 3
			2013
Cash and cash equivalents	Cash and cash equivalents		$	13,351			$	5,260	$	8,091		$	—

Short-term investments	Corporate bonds		45,187				—		45,187			—

Short-term investments	Government-sponsored enterprises		14,538				—		14,538			—

Short-term investments	Municipal bonds		9,441				—		9,441			—

	Total assets		$	82,517			$	5,260	$	77,257		$	—


Current liabilities	Current portion of contingent consideration in conjunction with acquisition of BioVectra		$	4,238			$	—	$	—		$	4,238

Current liabilities	Current portion of contingent consideration in conjunction with acquisition of Synacthen		25,000				—		—			25,000

Non-current liabilities	Contingent consideration in conjunction with acquisition of BioVectra		33,224				—		—			33,224

Non-current liabilities	Contingent consideration in conjunction with acquisition of Synacthen		115,066				—		—			115,066

	Total liabilities		$	177,528			$	—	$	—		$	177,528


			December 31,				Level 1		Level 2			Level 3
			2012
Cash and cash equivalents	Cash and cash equivalents		$	7,740			$	7,242	$	498		$	—

Short-term investments	Certificates of deposit		722				—		722			—

Short-term investments	Corporate bonds		47,878				—		47,878			—

Short-term investments	Government-sponsored enterprises		24,712				—		24,712			—

Short-term investments	Municipal bonds		1,393				—		1,393			—

	Total assets		$	82,445			$	7,242	$	75,203		$	—

The fair value of contingent consideration in conjunction with both the acquisition of BioVectra and Synacthen were determined to be Level 3 under the fair value hierarchy. The following table presents the fair value, valuation technique and related unobservable input for the Level 3 measurements:


	Fair Value			Valuation Technique	Unobservable Input	Rate
Contingent consideration in conjunction with the acquisition of Bio Vectra estimate	$	37,462		Probability weighted	Discount rate	5%
				discounted future cash flows
Contingent consideration in conjunction with the acquisition of Synacthen estimate	$	140,066		Probability weighted	Discount rate	5%
				discounted future cash flows
Investment securities are exposed to various risk factors, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have an adverse material impact on our results of operations or shareholders’ equity.
The following table represents a roll forward of the fair value of Level 3 instruments, comprised solely of the contingent consideration, including the current portion of the contingent consideration:


		December 31, 2013
Balance at beginning of period		$	—

Amounts acquired or issued		167,046

Change due to compensation expense		1,893

Change due to time value of money		4,528

Change due to foreign currency translation adjustment		(2,368		)
Changes in fair value		6,429

Balance at end of period		$	177,528

If inputs in our fair value models were to change, resulting in a change in our contingent consideration, we believe such change could result in a material change in our financial position.
Certain assets and liabilities are measured at fair value on a nonrecurring basis. In other words, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). At March 31, 2013, we had determined that the portion of the value of our purchased technology associated with our prior acquisition of Doral was impaired. This determination was based on a signed purchase agreement dated April 30, 2013 for the disposition of Doral. Based on the agreement, we did not recover and therefore wrote off $0.7 million as of March 31, 2013. During the year ended December 31, 2013, we sold the asset for $0.7 million, the residual net book value.

Goodwill_Intangibles_and_Purch

Goodwill, Intangibles and Purchased Technology	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill, Intangibles and Purchased Technology	'
	Goodwill, Intangibles and Purchased Technology
	Goodwill and intangibles acquired in conjunction with the acquisition of BioVectra, consists of the following (in thousands):


			December 31,
			2013
	Acquired intangibles		$	33,186

	Less accumulated amortization		(3,055		)
	Acquired intangibles, net		$	30,131

	Goodwill		$	20,464

	The following table summarizes the changes in the carrying amount of goodwill (in thousands):


	Balance at December 31, 2012		$	—

	Goodwill resulting from the acquisition of BioVectra		21,914

	Currency translation		(1,450		)
	Balance at December 31, 2013		$	20,464

	The following table provides a rollforward of goodwill by country (in thousands):


		December 31,			Additions from Purchase Accounting			Currency Translation			December 31,
		2012									2013
	United States	$	—		$	—		$	—		$	—

	Canada	—			21,914			(1,450		)	20,464

	Total	$	—		$	21,914		$	(1,450	)	$	20,464

	The following table provides a rollforward of the intangibles (in thousands):


		December 31,
		2013
		Gross Book Value			Accumulated Amortization			Currency Translation			Net Book Value
	Trademark	$	8,151		$	—		$	(577	)	$	7,574

	Patent	58			(15		)	(3		)	$	40

	Contracted customer relationships	17,208			(1,578		)	(1,154		)	$	14,476

	Non-contracted customer relationships	10,164			(1,462		)	(661		)	$	8,041

	Total acquired intangibles	$	35,581		$	(3,055	)	$	(2,395	)	$	30,131

	The following table summarizes the changes in the carrying amount of intangibles (in thousands):


	Balance at December 31, 2012		$	—

	Intangibles resulting from the acquisition of BioVectra		35,581

	Amortization expense		(3,055		)
	Currency translation		(2,395		)
	Balance at December 31, 2013		$	30,131

	Amortization expense for BioVectra's intangibles totaled $3.1 million for the year ended December 31, 2013. The estimated annual amortization expense for intangible assets is approximately $3.2 million in 2014, $3.2 million in 2015, $3.1 million in 2016, $2.8 million in 2017, $2.6 million in 2018 and $7.5 million thereafter. Amortizable intangible assets are amortized over 8 to 10 years (9 years average). Customer relationships are amortized on an accelerated basis over their useful lives.
	Intangibles acquired in conjunction with the acquisition of Synacthen, consists of the following (in thousands):


		December 31,				December 31,
		2013				2012
In process R&D asset		$	196,663			$	—

Less accumulated amortization		(5,212		)		—

In process R&D asset, net		$	191,451			$	—

Amortization expense for the intangible acquired in conjunction with the acquisition of Synacthen totaled $5.2 million for the year ended December 31, 2013. The estimated annual amortization expense for the intangible asset is approximately $9.8 million in 2014, $9.8 million in 2015, $9.8 million in 2016, $9.8 million in 2017, $9.8 million in 2018 and $142.4 million thereafter. The in process R&D asset will be amortized over 20 years. We believe that this is the appropriate period because of the anticipated 7-8 years of development and the anticipated 11-12 years of patent exclusivity available thereafter.
Purchased technology consisted of our acquisition costs for Doral. Amortization expense for purchased technology totaled $0.8 million (which included an impairment charge of $0.7 million), $1.3 million (which included an impairment charge of $1.0 million), and $0.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. During the year ended December 31, 2013, we sold the asset for $0.7 million, the residual net book value.

Preferred_Stock_And_Shareholde

Preferred Stock And Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Preferred Stock and Shareholders' Equity	'
	Preferred Stock and Shareholders’ Equity
	Preferred Stock
	At December 31, 2013 and 2012, we had 5,334,285 shares of Preferred Stock authorized, no par value, and no shares of Preferred Stock were issued and outstanding.
	Common Stock
	The holders of outstanding shares of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board of Directors out of assets legally available therefore, subject to the payment of preferential and participating dividends with respect to any preferred stock that may be outstanding. In the event of our liquidation, dissolution and winding-up of our business, the holders of our outstanding common stock are entitled to share ratably in all assets available for distribution after payment of all our liabilities, subject to the rights of any outstanding shares of preferred stock. The holders of our common stock are entitled to one vote per share.
	On February 29, 2008, our Board of Directors approved a stock repurchase plan that provides for the repurchase of up to 7 million shares of our common stock. Stock repurchases under this plan may be made through either open market or privately negotiated transactions in accordance with all applicable laws, rules and regulations. On May 29, 2009 and May 10, 2012, our Board of Directors increased the stock repurchase plan authorization by an additional 6.5 million shares and 5 million shares, respectively. On September 28, 2012, our Board of Directors increased the remaining shares authorized under the stock repurchase plan to 7 million shares.
	During the year ended December 31, 2012, we used $261.8 million of our cash to repurchase 6,759,861 shares of our common stock. During the year ended December 31, 2013, we used $53.1 million of our cash to repurchase 960,000 shares of our common stock. Under this share repurchase plan, we have repurchased a total of 17.0 million shares of our common stock for $363.0 million through December 31, 2013, at an average price of $21.40 per share. As of December 31, 2013, there are approximately 5.3 million shares authorized remaining under our stock repurchase plan. Additionally, we have repurchased 6.2 million shares outside of the approved share repurchase plan, for $30.3 million at an average purchase price of $4.93 per share. Total shares repurchased were 23.1 million for $393.3 million at an average price of $17.01 per share.
	Employee Stock Purchase Plan
	Our 2003 Employee Stock Purchase Plan, or ESPP, provides our employees the opportunity to purchase our common stock through accumulated payroll deductions. The ESPP was originally adopted by the Board of Directors on January 24, 2003 and approved by our shareholders on May 12, 2003. The ESPP was amended by the Board of Directors on February 27, 2006 and was approved by our shareholders on May 18, 2006.
	Currently the ESPP has 3,500,000 shares available for issuance, including shares previously issued. In April 2008, our Board further amended the ESPP to reduce the maximum offering period under the ESPP from 27 months to 6 months and to no longer allow employees the ability to increase their payroll contributions to the ESPP during an offering period.
	The purpose of the ESPP is to provide all of our employees with an opportunity to purchase our common stock through accumulated payroll deductions. Any person who is employed by us on the offering date, for at least 20 hours per week and more than five months in any calendar year, is eligible to participate in the ESPP. Under the ESPP, eligible employees could have up to 15% of their earnings withheld, subject to certain maximums, to be used to purchase shares of our common stock. Generally, the purchase price per share at which shares are sold under the ESPP is the lower of 85% of the fair market value of a share of our common stock on the first day of each offering period or 85% of the fair market value of a share of our common stock on the last day of each three month purchase period. During the years ended December 31, 2013, 2012 and 2011, 137,472, 92,030 and 90,650 shares, respectively, had been issued to participants.
	ESPP activity during 2013 was as follows:


			Number of			Weighted-
			Shares			Average Fair
						Value
	Available at December 31, 2012		682,080

	Purchases		(137,472	)		$	29.49

	Shares added to the Plan		—

	Available at December 31, 2013		544,608

	We use the Black-Scholes option–pricing model to estimate the fair value of the option element related to employees’ purchases under the ESPP included in the total share-based compensation expense recorded for the years ended December 31, 2013, 2012 and 2011. The determination of fair value using the Black-Scholes option-pricing model is affected by our stock price as well as similar assumptions used to value our stock-based awards.

	•	Volatility is based on the historical volatility of our common stock;

	•	Interest rate is based on the U.S. Treasury yield;

	•	Expected term represents the life of the option element; and

	•	Expected dividend yield is based on anticipated future dividends.


			Years Ended December 31,
			2013			2012			2011
	Weighted average volatility		52	%		110	%		53	%
	Risk-free interest rate		0.1	%		0.1	%		0.1	%
	Expected term (in years)		0.25			0.25			0.25

	Expected dividend yield		2.4	%		1.4	%		—	%
	Stock Compensation Plans
	Stock Options
	We have options outstanding to purchase shares of our common stock under the following plans:

	•	2006 Equity Incentive Award Plan that provides for the grant of equity incentives to employees, members of our Board of Directors, and consultants;

	•	1992 Employee Stock Option Plan that provided for the grant of stock options to employees, members of our Board of Directors, and consultants; and

	•	2004 Non-Employee Directors’ Equity Incentive Plan that provides for the grant of equity incentives to non-employee members of our Board of Directors.
	In May 2006, our shareholders approved the adoption of the 2006 Equity Incentive Award Plan. Upon the adoption of the 2006 Equity Incentive Award Plan, we ceased grants under our 1992 Employee Stock Option Plan. The 2006 Equity Incentive Award Plan provides for the grant of incentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants, stock appreciation rights, restricted stock units and dividend equivalents. Equity incentives under the 2006 Equity Incentive Award Plan and the 1992 Employee Stock Option Plan generally include four year vesting periods, an exercise price that equals the fair market value of our common stock on the date of grant, and maximum terms of ten years. Restricted stock awards entitle the recipient to full dividend and voting rights. Non-vested shares are restricted as to disposition and subject to forfeiture under certain circumstances. In May 2011, the shareholders approved an amendment to the 2006 Equity Incentive Award Plan to increase the number of shares of common stock authorized for issuance by 3,500,000 shares. The aggregate number of shares of common stock authorized for issuance under the 2006 Equity Incentive Award Plan is 9,750,000 shares.
	Our 2004 Non-Employee Directors’ Equity Incentive Plan provides for the granting of 25,000 stock options to purchase common stock upon appointment as a non-employee director and 15,000 stock options each January thereafter for continuing service upon reappointment. Such stock option grants vest over four years. In addition, 10,000 stock options are granted to members of one or more committees of the Board of Directors and an additional 7,500 stock options to the chairs of one or more committees. Such stock option grants are fully vested at the time of grant. As originally approved by shareholders, such option grants had an option exercise price equal to 85% of the fair market value on the date of grant. However, in May 2004, our Board of Directors approved an amendment to the 2004 Non-Employee Directors’ Equity Incentive Plan to provide that all option grants be made at an exercise price equal to 100% of the fair market value of our common stock on the date of grant. The maximum term of the stock options granted is 10 years. Under the terms of the 2004 Non- Employee Directors’ Equity Incentive Plan, 1,250,000 shares of our common stock were authorized for grant. In May 2011, with the amendment of the 2006 Equity Incentive Award Plan, we ceased grants under our 2004 Non-Employee Directors' Equity Incentive Plan. All future grants to non-employee directors will be issued under the 2006 Equity Incentive Award Plan out of authorized shares.
	During the years ended December 31, 2013, 2012 and 2011, we granted options, including performance-based options, to employees and non-employee directors to purchase approximately 426,896, 2,154,909, and 1,734,100 shares of our common stock, respectively, under the 2006 Equity Incentive Award Plan.
	As of December 31, 2013, a total of 2,570,483 shares of common stock were reserved for issuance under both the 2006 Equity Incentive Award Plan and the 2004 Non-Employee Directors’ Equity Incentive Plan. A summary of our stock option activity and related information during 2012 follows:


			Stock			Weighted-				Weighted-		Aggregate
			Options			Average				Average		Intrinsic Value
						Exercise				Remaining
						Price				Contractual
										Term
									(In years)
Outstanding at December 31, 2012		6,446,618			$	16.52

Granted		426,896			35.66

Exercised		(1,692,920	)		9.44

Forfeited or expired		(118,489	)		30.16

Outstanding at December 31, 2013		5,062,105			$	20.18			6.98		$	173,920,567

Options vested and expected to vest at December 31, 2013		4,993,859			$	19.99			6.96		$	172,493,803

Exercisable at December 31, 2013		3,442,547			$	15.02			6.38		$	135,750,172

Aggregate intrinsic value is the sum of the amounts by which the quoted market price of our stock exceeded the exercise price of the stock options at December 31, 2013 for those stock options for which the quoted market price was in excess of the exercise price (“in-the-money options”). The total intrinsic value of stock options exercised was $74.9 million, $29.9 million and $57.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. Cash received for the exercise of options was $16.0 million for the year ended December 31, 2013.
Restricted Stock Awards
During the years ended December 31, 2013, 2012 and 2011, we granted a total of 829,899, 777,524, and 31,762 shares of restricted common stock (including performance-based awards granted in 2013), respectively, to employees under the 2006 Equity Incentive Award Plan. Restrictions on these shares will expire and related charges are being amortized as earned over the vesting period of four years. During the first and second quarter of 2013, we issued 207,250 shares of performance-based restricted stock awards. These performance-based restricted stock awards include a one-time performance achievement and vest according to the degree at which the performance milestone is achieved. At December 31, 2013, we determined achievement of the milestone was reasonably probable and estimable at a level equal to one-third the value and, therefore, recorded an appropriate amount of stock-based compensation expense associated with such grants.
We base the amount of unearned compensation recorded on the market value of the shares on the date of issuance. Expenses related to the vesting of restricted stock were $14.6 million (which includes $1.6 million related to the performance-based awards), $1.8 million and $163,000 for the years ended December 31, 2013, 2012 and 2011, respectively. Total fair value of awards vested were $12.7 million, $0.7 million and $115,000 for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2013, there was approximately $25.2 million of unamortized compensation cost related to restricted stock awards, which we expect to recognize ratably over the vesting period of four years.
Restricted stock activity during 2013 was as follows:


		Number			Weighted-
		of Shares			Average Fair
					Value
Non-vested shares at December 31, 2012		789,479			$	26.42

Granted		829,899			$	34.14

Released		(205,181	)		$	26.5

Forfeited or expired		(51,033	)		$	28.34

Non-vested shares at December 31, 2013		1,363,164			$	30.99

Restricted Stock Units
During the year ended December 31, 2013, we granted a total of 10,515 shares of restricted share units to certain employees under the 2006 Equity Incentive Award Plan. We did not grant any restricted stock units during the years ended December 31, 2012 and 2011. Restrictions on these shares will expire and related charges are being amortized as earned over the vesting period of four years.
Expense related to the vesting of restricted stock units was $9,000 for the year ended December 31, 2013. No expense was recorded for the years ended December 31, 2012 and 2011. At December 31, 2013, there was approximately $0.5 million of unamortized compensation cost related to restricted stock units, which we expect to recognize ratably over the vesting period of four years.
Restricted stock unit activity during 2013 was as follows:


		Number			Weighted-				Weighted-		Aggregate
		of Shares			Average Fair Value				Average		Intrinsic Value
									Remaining
									Contractual
									Term
Outstanding at December 31, 2012		—			$	—

Granted		10,515			$	51.69

Released		—			$	—

Forfeited or expired		—			$	—

Outstanding at December 31, 2013		10,515			$	—			2.17		$	572,541.75

Vested and expected to vest at December 31, 2013		9,622			$	—			2.12		$	523,915.46

Exercisable at December 31, 2013		—			$	—			0		$	—

Fair Value of Stock-Based Awards
The weighted average fair value of equity instruments granted during 2013, 2012 and 2011 was as follows:


		Weighted Average Fair Value
		2013				2012				2011
Stock options		$	35.66			$	36.16			$	16.89

ESPP Purchases		$	29.49			$	28.91			$	14.98

Restricted Stock Awards		$	34.14			$	26.86			$	27.28

Restricted Stock Units		$	51.69			$	—			$	—


At December 31, 2013, there was $25.8 million of total unrecognized compensation cost related to unvested restricted stock awards and restricted stock units and $20.4 million of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.2 years.
We use the Black-Scholes option–pricing model to estimate the fair value of stock-based awards. The determination of fair value using the Black-Scholes option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.

•	Volatility is based on the historical volatility of our common stock. During 2010, we reviewed our methodology for calculating volatility and, in doing so we shortened the look-back period to represent the time period following the implementation of our Acthar-centric pricing strategy in late 2007. This resulted in a lower volatility that, we believe, is a better representation of our current market condition.

•	Interest rate is based on the U.S. Treasury yield.

•	Expected term was based on the historical experience of similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and the expectations of future employee behavior.

•	Expected dividend yield is based on future anticipated dividend rates.
The total number of stock option awards expected to vest is adjusted by estimated forfeiture rates. The weighted average assumptions used for the years ended December 31, 2013, 2012 and 2011 and the resulting estimates of weighted average fair value per share of options granted during those periods are as follows:



		Years Ended December 31,
		2013			2012			2011
Volatility		71	%		72	%		61	%
Interest rate		0.4-0.8			0.3-0.5			0.5-2.4

Forfeiture rate		4.05	%		4.99	%		7.61	%
Expected term (in years)		3.6			3.6			3.4

Expected dividend yield		2.6	%		3.2	%		—	%
Share-based compensation expense related to employees and non-employee members of the Board of Directors has been included in the accompanying Consolidated Statements of Income for the years ended December 31, 2013, 2012 and 2011 as follows (in thousands):


		Years Ended December 31,
		2013				2012				2011
Selling and marketing		$	10,897			$	5,360			$	4,236

General and administrative		12,302				7,467				1,884

Research and development		5,554				2,965				1,206

Total share-based compensation expense		$	28,753			$	15,792			$	7,326

Indemnifications_Commitments_A

Indemnifications, Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Indemnifications, Commitments and Contingencies	'
	Indemnifications, Commitments and Contingencies
	Indemnifications
	As permitted under California law and in accordance with our Bylaws, we indemnify our officers and directors and certain of our employees for certain events or occurrences while the officer, director or employee is or was serving at our request in such capacity. The potential future indemnification limit is to the fullest extent permissible under California law; however, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. Accordingly, we had no liabilities recorded for these agreements as of December 31, 2013 and 2012.
	*Employment Agreements*
	We have entered into employment and severance agreements with our corporate officers that provide for, among other things, base compensation and/or other benefits in certain circumstances in the event of termination or a change in control. In addition, certain of the agreements provide for the accelerated vesting of outstanding unvested stock options upon a change in control.
	Leases
	We lease office facilities under various operating lease agreements, with remaining terms that extend to 2018. We have also entered into automobile and office equipment leases, with remaining terms that extend to 2017. As of December 31, 2013, we have made approximately $77,000 in cash deposits related to operating leases. Provisions of the facilities leases provide for abatement of rent during certain periods and escalating rent payments during the term. Rent expense is recognized on a straight-line basis over the term of the lease. Accordingly, rent expense recognized in excess of rent paid is reflected as deferred rent. Rent expense on the facilities and equipment during 2013, 2012 and 2011 was $1.2 million, $1.0 million and $1.0 million, respectively.
	Future annual minimum payments under operating leases are as follows (in thousands):



	Years Ending December 31,
	2014	$	5,651

	2015	4,173

	2016	2,123

	2017	1,085

	2018	291

	Thereafter	331

	Total	$	13,654

	As of December 31, 2013 we leased space in three buildings with lease terms expiring in 2014, 2017 and 2018. We leased land for our BioVectra operations with a lease term expiring in 2051, subject to 10 year revaluation clause based upon comparable land values at the date of revaluation. We have also entered into various office equipment leases and automobile leases, the terms of which are typically three years. Annual rent expense for all of our facilities, equipment and automobile leases for the year ended December 31, 2013 was approximately $4.0 million.
	For our U.S. operations, we lease space primarily in these locations:

	•	We lease 30,000 square feet of laboratory and office space in Hayward, California under a master lease that expires in May 2018. This facility is occupied by our Commercial Development, Sales and Marketing, Medical Affairs, Contract Manufacturing, Quality Control and Quality Assurance departments.

	•	We lease 15,600 square feet of office space in Ellicott City, Maryland under a lease agreement that expires in October 2017. This facility is occupied by our Product Development and Regulatory Affairs departments.

	•	We lease 7,900 square feet of office space in Anaheim, California under a lease agreement that expires in October 2014. This facility is occupied by our Executive, Finance and Administration departments, and serves as our corporate headquarters.
	Legal Proceedings
	We operate in a highly regulated industry. We are subject to the regulatory authority of the Securities and Exchange Commission, or SEC, the FDA and numerous other federal and state governmental agencies including state attorney general offices, which have become more active in investigating the business practices of pharmaceutical companies.
	Glenridge Litigation
	In June 2011, Glenridge Pharmaceuticals LLC, or Glenridge, filed a lawsuit against us in the Superior Court of California, Santa Clara County, alleging that we had underpaid royalties to Glenridge, in connection with the timing of the impact of various offsets in the calculation of net sales. In August 2012, we filed a separate lawsuit against the three principals of Glenridge, as well as Glenridge, challenging the enforceability of our agreement with Glenridge. Our lawsuit alleges that Kenneth Greathouse breached his fiduciary duties to the Company and that his partners at Glenridge aided and abetted his breach. In August 2013, the two lawsuits were consolidated into one case in the Superior Court of California, Santa Clara County. We have filed a motion for summary adjudication which seeks to have our agreement with Glenridge declared unenforceable. The motion is based on laws that govern self-dealing transactions. A hearing on this motion is currently scheduled on March 6, 2014.
	USAO Investigation
	On September 21, 2012, we became aware of an investigation by the United States Attorney's Office, or the USAO, for the Eastern District of Pennsylvania regarding our promotional practices. Following our September 24, 2012 announcement of this investigation, we received a subpoena from the USAO for information relating to our promotional practices. We have been informed by the USAO for the Eastern District of Pennsylvania that the USAO for the Southern District of New York and the SEC are also participating in the investigation to review our promotional practices and related matters. We continue to cooperate with the USAO and the SEC with regard to this investigation.
	Putative Class Action Securities Litigation
	On September 26, 2012, a putative class action lawsuit was filed against us and certain of our officers and directors in the United States District Court for the Central District of California, captioned John K. Norton v. Questcor Pharmaceuticals, et al., No. SACv12-1623 DMG (FMOx). The complaint purports to be brought on behalf of shareholders who purchased our common stock between April 26, 2011 and September 21, 2012. The complaint generally asserts that we and certain of our officers and directors violated sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, by making allegedly false and/or misleading statements concerning the clinical evidence to support the use of Acthar for indications other than infantile spasms, the promotion of the sale and use of Acthar in the treatment of MS and nephrotic syndrome, reimbursement for Acthar from third-party insurers, and our outlook and potential market growth for Acthar. The complaint seeks damages in an unspecified amount and equitable relief against the defendants. This lawsuit has been consolidated with four subsequently-filed actions asserting similar claims under the caption: In re Questcor Securities Litigation, No. CV 12-01623 DMG (FMOx). On October 1, 2013, the District Court granted in part and denied in part our motion to dismiss the consolidated amended complaint. On October 29, 2013, we filed an answer to the consolidated amended complaint.
	Federal Shareholder Derivative Litigation
	On October 4, 2012, another alleged shareholder filed a derivative lawsuit in the United States District Court for the Central District of California captioned Gerald Easton v. Don M. Bailey, et al., No. SACV12-01716 DOC (JPRx). The suit asserts claims substantially identical to those asserted in the do Valle derivative action described below against the same defendants. This lawsuit has been consolidated with five subsequently-filed actions asserting similar claims under the caption: In re Questcor Shareholder Derivative Litigation, CV 12-01716 DMG (FMOx). Following the resolution of the motion to dismiss in the consolidated putative securities class action, the court issued an order staying the federal derivative action until the earlier of: (a) sixty (60) days after the resolution of any motion for summary judgment filed in the putative class action lawsuit, (b) sixty (60) days after the deadline to file a motion for summary judgment in the putative class action lawsuit, if none is filed, or (c) the execution of any settlement agreement (including any partial settlement agreement) to resolve the putative class action lawsuit.
	State Shareholder Derivative Litigation
	On October 2, 2012, an alleged shareholder filed a derivative lawsuit purportedly on behalf of the Company against certain of our officers and directors in the Superior Court of the State of California, Orange County, captioned Monika do Valle v. Virgil D. Thompson, et al., No. 30-2012-00602258-CU-SL-CXC. The complaint asserts claims for breach of fiduciary duty, abuse of control, mismanagement and waste of corporate assets arising from substantially similar allegations as those contained in the putative securities class action described above, as well as from allegations relating to sales of our common stock by the defendants and repurchases of our common stock. The complaint seeks an unspecified sum of damages and equitable relief. On October 24, 2012, another alleged shareholder filed a derivative lawsuit purportedly on behalf of the Company against certain of our officers and directors in the Superior Court of the State of California, Orange County, captioned Jones v. Bailey, et al., Case No. 30-2012-00608001-CU-MC-CXC. The suit asserts claims substantially identical to those asserted in the do Valle derivative action. On February 19, 2013, the court issued an order staying the state derivative actions until the putative federal securities class action and federal derivative actions are resolved.
	Put Options Securities Action
	In March 2013, individual traders of put options filed a securities complaint in the United States District Court for the Central District of California captioned David Taban, et al. v. Questcor Pharmaceuticals, Inc., No. SACV13-0425. The complaint generally asserts claims against us and certain of our officers and directors for violations of the Exchange Act and for state law fraud and fraudulent concealment based on allegations similar to those asserted in the putative securities class action described above. The complaint seeks compensatory damages in an amount equal to $5 million and punitive damages of an unspecified amount. Following the resolution of the motion to dismiss in the consolidated putative securities class action, the court issued an order staying this action until the earlier of: (a) sixty (60) days after the resolution of any motion for summary judgment filed in the putative class action lawsuit, (b) sixty (60) days after the deadline to file a motion for summary judgment in the putative class action lawsuit, if none is filed, or (c) the execution of any settlement agreement (including any partial settlement agreement) to resolve the putative class action lawsuit.
	Retrophin Litigation
	In January 2014, Retrophin Inc. filed a lawsuit against us in the United States District Court for the Central District of California, alleging a variety of federal and state antitrust violations based on our acquisition from Novartis of certain rights to develop, market, manufacture, distribute, sell and commercialize Synacthen. Our response to the complaint is due on or before March 6, 2014.
	Conclusion
	We believe that the probability of unfavorable outcome or loss related to these matters and an estimate of the amount or range of loss, if any, from an unfavorable outcome are not determinable at this time. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations, defending any claims raised, and any resulting fines, restitution, damages and penalties, settlement payments or administrative actions, as well as any related actions brought by shareholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business.
	*Commitments*
	During the year ended December 31, 2011, we entered into an agreement with a third party vendor to provide potency and toxicity testing on Acthar prior to releasing the product for commercial distribution. Beginning on January 1, 2012, the agreement provides for a maximum number of tests to be performed each year. Tests performed in excess of the maximum are to be paid on a per test basis. We have been in compliance with the terms of our agreement with this third party vendor.
	We have an agreement with BioVectra (our wholly-owned subsidiary, which eliminates upon consolidation) to produce the API used in Acthar. The agreement requires the production of a minimum number of kilograms of the Acthar API during the term. The agreement terminated on December 31, 2007 and was extended in January 2008 through December 2010. During the fiscal year ended December 31, 2010, we entered into a new agreement with BioVectra, which terminates 12 months after written notice by either party. Under the terms of the new agreement, we are obligated to purchase a minimum amount of Acthar API and will not purchase in excess of a certain amount of Acthar API per year. We have been in compliance with the terms of our agreement with BioVectra.
	On January 18, 2013, we completed our acquisition of BioVectra Inc. We acquired 100% of the issued and outstanding shares of BioVectra for $50.3 million utilizing cash on hand. The former shareholders of BioVectra could receive additional cash consideration of up to C$50.0 million based on BioVectra's financial results over the next three years. As of December 31, 2013, the estimated value of the contingent consideration of $37.5 million has been recorded as a liability in our condensed consolidated balance sheets ($4.2 million has been recorded as the current portion of the contingent consideration). In 2013, BioVectra met its performance milestone for the year and earned an additional C$5.0 million in consideration.
	On June 11, 2013, the Effective Date, we acquired from Novartis a license to develop, market, manufacture, distribute, sell and commercialize Synacthen and Synacthen Depot for all uses in humans in the United States. Under the terms of the transaction agreements, we paid Novartis an upfront consideration of $60 million. We will also be making annual cash payments of $25 million on each of the first, second and third anniversaries of the Effective Date, a potential additional annual cash payment on each anniversary subsequent to the third anniversary until we obtain the first approval of the FDA related to the products, or the FDA Approval, and a milestone payment upon our receipt of the FDA Approval. If we successfully obtain the FDA Approval, we will pay an annual royalty to Novartis based on a percentage of the net sales of the product in the U.S. market until the maximum payment is met. The first three annual payments aggregating to $75 million are secured by a letter of credit and classified as restricted cash on the Condensed Consolidated Balance Sheets. In no event will the total payments related to this transaction exceed $300 million. As of December 31, 2013, we recorded an asset (because it was determined that the intangible asset has alternative future use) related to the acquisition of Synacthen of $191.5 million and a corresponding liability of $140.1 million. The asset and liability (which was determined to be a derivative) were originally valued using a weighted discounted probability model. The asset is considered to be definite-lived and is amortized over its useful life to research and development expense. The liability is reviewed each reporting period for any changes in the probability assumptions and for changes due to the passage of time.
	We pay an annual royalty to the prior owner of Acthar equal to 1% of net sales in excess of $10 million. We also incur quarterly payments to Glenridge Pharmaceuticals, LLC under a purported Royalty Agreement and Release equal to three percent 3% of net sales. See above under "Litigation." Royalty expense for the years ended December 31, 2013, 2012 and 2011 was $30.4 million, $20.2 million and $8.5 million, respectively, which is included in Cost of Sales in the accompanying Consolidated Statements of Income and Comprehensive Income.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Income before income taxes is attributed to the following geographic locations for the years ended December 31, 2013, 2012 and 2011 (in thousands):


			Years Ended December 31,
			2013				2012				2011
	Federal		$	449,285			$	297,230			$	113,745

	Foreign		(9,745		)		—				—

	Income before income taxes		$	439,540			$	297,230			$	113,745

	The Company’s foreign earnings attributable to its foreign operating entities will be permanently reinvested in such foreign jurisdictions and, therefore, no deferred tax liabilities for U.S. income taxes on undistributed earnings are recorded. The determination of the unrecognized deferred tax liability for the temporary differences related to these undistributed earnings is not practicable. At December 31, 2013, the undistributed earnings amount to $1.0 million. In addition, the Company has a provincial tax holiday in Canada that expires on April 1, 2017.
	The components of the income tax expense are as follows (in thousands):


			Years Ended December 31,
			2013				2012				2011
	Current:
	Federal		$	158,914			$	97,267			$	38,575

	State		1,615				2,047				475

	Foreign		1,251				—				—

			161,780				99,314				39,050

	Deferred:
	Federal		(13,026		)		344				(4,782		)

	State		(64		)		(103		)		(114		)
	Foreign		(1,759		)		—				—

			(14,849		)		241				(4,896		)

	Total income tax expense		$	146,931			$	99,555			$	34,154

	A reconciliation between the U.S. statutory tax rate and our effective tax rate is as follows:


			Years Ended December 31,
			2013			2012			2011
	Tax at U.S. statutory rate		35	%		35	%		35	%
	State income taxes, net		0.4	%		0.7	%		0.2	%
	Change in valuation allowance		—	%		—	%		—	%
	Orphan drug tax credit		—	%		—	%		(2.1	)%
	Foreign rate differential		0.7	%		—	%		—	%
	Other		(2.7	)%		(2.2	)%		(3.1	)%
	Effective tax rate		33.4	%		33.5	%		30	%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amount used for income tax purposes, as well as net operating loss and tax credit carryforwards. Significant components of our deferred tax assets and liabilities are as follows (in thousands):


			Years Ended December 31,
			2013				2012
	Deferred tax assets:
	Net operating loss carryforwards		$	1,879			$	2,117

	Research and development credits		68				92

	Sales-related reserves		4,656				5,803

	Stock-based compensation		12,575				8,006

Intangible asset		1,121				—

Other, net		12,240				2,219

Total deferred tax assets		32,539				18,237

Valuation allowance		(920		)		(981		)
		31,619				17,256

Deferred tax liabilities:
Capital assets		(10,569		)		$	—

Net deferred taxes		$	21,050			$	17,256

We recognize valuation allowances on deferred tax assets reported if, based on the weight of the evidence, we believe that it is “more likely than not” that some or all of our deferred tax assets will not be realized. We evaluate deferred tax assets quarterly to assess the likelihood of realization, which is ultimately dependent upon our generating future taxable income. Our valuation allowance decreased $61,000 in 2013 and increased $36,000 in 2012 . This allowance was associated with our California net operating losses and research and development tax credits which we do not anticipate to fully utilize and therefore have established a valuation allowance on those deferred tax assets.
At December 31, 2013, we had federal and state net operating loss carryforwards of $2.9 million and $15.3 million, respectively, and California research and development tax credits of $0.1 million, respectively. All federal net operating loss carryforwards are subject to annual limitations as a result of federal ownership change limitations, and will be available from 2013 through 2018, under those limitations. In addition, as of December 31, 2013, the 1994 - 2011 tax years remain subject to examination in the U.S. and various state tax jurisdictions due to net operating losses that are being carried forward. The Company is currently undergoing a Federal exam, however the Company does not believe that such exam will have a material adverse effect on the consolidated financial statements.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):


		Years Ended
		December 31,
		2013				2012
Balance at beginning of year		$	1,223			$	1,274

Increase / (decrease) of unrecognized tax benefits taken in prior years		377				(437		)

Increase of unrecognized tax benefits related to current year		(319		)		386

Balance at end of year		$	1,281			$	1,223

The unrecognized tax benefits, if recognized in full, would reduce our income tax expense by $1.3 million. Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of tax expense. As of December 31, 2013 and 2012, our accrual for interest and penalties on any unrecognized tax benefits was $78,000 and $106,000, respectively. We expect unrecognized tax benefits to decrease by approximately $0.5 million over the next 12 months as a result of the settlement of an IRS examination.

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
Defined Contribution Plan	Dec. 31, 2013
Postemployment Benefits [Abstract]	'
Defined Contribution Plan	'
	Defined Contribution Plan
	We have a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended, covering substantially all full-time U.S. employees. Participating employees may contribute up to 60% of their eligible compensation up to the annual Internal Revenue Service contribution limit. This plan allows for discretionary contributions by us. Employer matching contributions for the years ended December 31, 2013, 2012 and 2011 were $1.5 million, $1.0 million and $0.3 million, respectively.

Quarterly_Results_Of_Operation

Quarterly Results Of Operations	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Results of Operations	'
	Quarterly Results of Operations (unaudited)
	The following table sets forth a summary of our unaudited quarterly operating results for each of the last eight quarters in the period ended December 31, 2013. We have derived this data from our unaudited consolidated interim financial statements that, in our opinion, have been prepared on substantially the same basis as the audited financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with our financial statements and notes thereto included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands, except earnings per share).

	QUARTERLY FINANCIAL INFORMATION (UNAUDITED)



			Quarter Ended
			12/31/13		9/30/13		6/30/13		3/31/13
	Net sales		$	242,881	$	236,346	$	184,573	$	135,129

	Cost of sales		20,921		20,034		17,221		16,189

	Income tax expense		48,839		45,668		33,969		18,455

	Net income		89,981		94,441		69,123		39,064

	Comprehensive income		88,430		95,372		67,644		37,870

	Net income per share applicable to common shareholders (1):
	Basic		$	1.51	$	1.6	$	1.17	$	0.68

	Diluted		$	1.44	$	1.52	$	1.12	$	0.65

	Dividend declared per common share		$	0.6	$	—	$	0.25	$	0.25


			Quarter Ended
			12/31/12		9/30/12		6/30/12		3/31/12
	Net sales		$	160,533	$	140,339	$	112,452	$	95,968

	Cost of sales		9,157		7,499		6,379		5,520

	Income tax expense		32,987		27,836		19,724		19,008

	Net income		61,940		55,687		41,505		38,543

	Comprehensive income		61,926		55,700		41,491		38,634

	Net income per share applicable to common shareholders (1):
	Basic		$	1.07	$	0.95	$	0.68	$	0.61

	Diluted		$	1.03	$	0.91	$	0.65	$	0.58

	Dividend declared per common share		$	0.2	$	0.2	$	—	$	—




	(1	)	Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Schedule_II_Valuation_And_Qual

Schedule II Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule II - Valuation and Qualifying Accounts	'
	FINANCIAL STATEMENT SCHEDULES (ITEM 15(a)(2))
	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
	Years Ended December 31, 2013, 2012 and 2011



		Balance at		Additions/		Deductions		Balance at
		Beginning		(Deductions)		and		End of
		of Period		Charged to		Write-Offs		Period
				Income
		(In thousands)
	Reserves for uncollectible accounts

	December 31, 2013	$	—	$	475	$	—	$	475

	December 31, 2012	$	—	$	—	$	—	$	—

	December 31, 2011	$	25	$	—	$	25	$	—


	Reserves for obsolete and excess inventories

	December 31, 2013	$	52	$	1,329	$	52	$	1,329

	December 31, 2012	$	—	$	52	$	—	$	52

	December 31, 2011	$	158	$	—	$	158	$	—


	Sales-related reserves
	December 31, 2013	$	37,376	$	52,129	$	54,135	$	35,370

	December 31, 2012	$	34,119	$	64,707	$	61,450	$	37,376

	December 31, 2011	$	21,511	$	50,658	$	38,050	$	34,119

	All other financial statement schedules are omitted because the information described therein is not applicable, not required or is furnished in the financial statements or notes thereto.

Organization_And_Summary_Of_Si1

Organization And Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
	The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income in shareholders' equity. Foreign currency transaction gains and losses are included in the results of operations in our Consolidated Statements of Income and Comprehensive Income.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP, requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Our significant estimates include our estimates for sales-related reserves, valuation and impairment of intangibles and goodwill, deferred tax assets and tax liabilities, share-based compensation and estimating the fair value of our contingent consideration in conjunction with the acquisition of both BioVectra and Synacthen, among others.
Reclassifications	'
	Reclassifications
	Certain comparative prior year amounts in the Consolidated Financial Statements and accompanying notes have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net income.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Our financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, dividends payable, accrued liabilities, current and long-term debt and derivatives (primarily associated with the contingent consideration in conjunction with the acquisition of Synacthen). We believe that the fair value of these financial instruments approximate the reported carrying amounts.
Cash Equivalents and Short-Term Investments	'
	Cash Equivalents and Short-Term Investments
	We consider highly liquid investments with maturities from the date of purchase of three months or less to be cash equivalents. We classify available-for-sale debt instruments with maturities at the date of purchase greater than three months as short-term investments.
	We carry available-for-sale securities at fair value, with the unrealized gains and losses, if any, reported in a separate component of shareholders’ equity. If we deem the decline in value to be other-than-temporary and we intend to sell such securities before their full cost can be recovered, we write down such securities to fair value and we charge the loss to net realized losses on investments. We use significant judgment in the determination of when an other-than-temporary decline in value has occurred. We evaluate our investment securities for other-than-temporary declines based on quantitative and qualitative factors. As of December 31, 2013 none of our investments had an other-than-temporary decline in valuation, and no other-than-temporary losses were recognized during the years ended December 31, 2013, 2012 and 2011. We base the cost of securities sold on the specific identification method. We include realized gains and losses, if any, in the accompanying Consolidated Statements of Income and Comprehensive Income, in Interest and other (expense) income, net.
Concentration of Risk	'
	Concentration of Risk
	Financial instruments that subject us to a significant concentration of credit risk principally consist of cash and cash equivalents, short-term investments and accounts receivable. We invest our cash in high credit quality government and corporate debt instruments and believe the financial risks associated with these instruments are minimal.
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. Beginning January 1, 2013, all of our non-interest bearing cash balances were insured up to $250,000 per depositor at each financial institution.
	We extend credit to our specialty distributor, which accounts for approximately 95% of our gross product sales and 92% of our accounts receivable. We have not experienced material credit losses on our customer accounts.
Inventories	'
	Inventories
	We state inventories, net of allowances, at the lower of cost or market value. For our Acthar product, cost is determined by the first-in, first-out method. For our production materials and supplies, work-in-process and finished goods at our contract manufacturer, cost is determined on an average cost basis.
	We review inventory periodically for slow-moving or obsolete status. We adjust our inventory if we do not expect to recover the cost of inventory. We would record a reserve to adjust inventory to its net realizable value when any of the following occur: (i) a product is close to expiration and we do not expect it to be sold, (ii) a product has reached its expiration date or (iii) we do not expect a product to be saleable. In determining the reserves for these products, we consider factors such as the amount of inventory on hand and its remaining shelf life, and current and expected market conditions, including management forecasts and levels of competition. We have evaluated the current level of inventory considering historical trends and other factors, and based on our evaluation, have recorded adjustments to reflect inventory at its net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to assess the future demand for our products in order to categorize the status of such inventory items as slow-moving, obsolete or in excess-of-need. These future estimates are subject to the ongoing accuracy of our forecasts of market conditions, industry trends, competition and other factors. Differences between our estimated reserves and actual inventory adjustments have been immaterial, and we account for such adjustments in the current period as a change in estimate.
Property and Equipment	'
	Property and Equipment
	We record property and equipment at cost. We depreciate equipment and furniture using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. We amortize equipment acquired under capital leases over the estimated useful life of the assets and include such amortization in depreciation expense.
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	We determine the estimated fair values of goodwill and intangible assets with definite and/or indefinite lives based on valuations performed at the time of their acquisition in accordance with FASB ASC 350. Such valuations utilize forecasted financial information. In addition, certain amounts paid to third parties, such as our In Process R&D asset related to the acquisition of Synacthen, are capitalized and included in intangible assets on the accompanying consolidated balance sheets.
	Goodwill and indefinite-lived intangibles are tested for impairment annually and in interim periods if certain events occur indicating the fair value may be below its carrying value using a two-step process. The first step is to identify a potential impairment, and the second step measures the amount of the impairment loss, if any. Goodwill is impaired if the carrying amount of a reporting unit’s goodwill exceeds its estimated fair value. We performed our annual goodwill and indefinite-lived impairment assessment as of December 31, 2013, noting no impairment.
	Definite lived intangibles are amortized on an accelerated or straight-line basis over their estimated useful life. This determination is made based on the specific asset and the timing of recoverability from expected future cash flows.
	We review the carrying value of our definite-lived intangibles and long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable. These assets are impaired when undiscounted expected future cash flows are less than the carrying value. Our judgments related to the expected useful lives of definite-lived intangibles and long-lived assets and our ability to realize undiscounted cash flows in excess of the carrying amounts of such assets are affected by factors such as ongoing maintenance and improvements of the assets, changes in economic conditions, our ability to successfully launch products, and changes in operating performance. In addition, we regularly evaluate our long-lived assets and may accelerate depreciation over the revised useful life if the asset has limited future value. During the years ended December 31, 2013, 2012 and 2011, we recorded impairment charges for purchased technology and goodwill of $0.7 million, $1.0 million and $0.3 million, respectively.
	As this process involves management making certain estimates and because these estimates form the basis of the determination of whether or not an impairment charge should be recorded, these estimates are considered to be critical accounting estimates. We will continue to assess the carrying value of our goodwill, intangible assets and long-lived assets in accordance with applicable accounting guidance.
Income Taxes	'
	Income Taxes
	We account for income taxes under the provisions of Accounting Standards Codification 740, “Income Taxes”, or ASC 740. We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.
	As part of the process of preparing our consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating our tax exposure under the most current tax laws and assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets.
	We regularly assess the likelihood that we will be able to recover our deferred tax assets, which is ultimately dependent on us generating future taxable income. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. If it is not considered “more likely than not” that we will recover our deferred tax assets, we will increase our provision for taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable. Changes in the valuation allowance based on our assessment will result in an income tax benefit if the valuation allowance is decreased and an income tax expense if the valuation allowance is increased.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue in accordance with Accounting Standards Codification 605, “Revenue Recognition-Products,” or ASC 605. Pursuant to ASC 605, we recognize revenue when we have persuasive evidence that an arrangement, agreement or contract exists, when each of the following three criteria are satisfied: (i) title for our product and risk of loss have passed to our customer, (ii) the price we charge for our product is fixed or is readily determinable, and (iii) we are reasonably assured of collecting the amounts owed under the resulting receivable. We do not require collateral from our customers.
Product Exchanges	'
	Product Exchanges
	Acthar has a shelf life of 18 months from the date of manufacture. We authorize Acthar exchanges for expiring and expired product in accordance with our stated return policy, which allows the specialty distributor we work with to return product within one month of its expiration date and for a period up to three months after such product has reached its expiration date.
Share-Based Compensation	'
	Share-Based Compensation
	We recognize compensation expense for all share-based awards made to employees and directors. The fair value of share-based awards is estimated at grant date using an option pricing model and the portion that is ultimately expected to vest is recognized as compensation cost over either (1) the requisite service period or (2) the performance period.
	Since share-based compensation is recognized only for those awards that are ultimately expected to vest, we have applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised, if necessary, in future periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards. The determination of fair value using the Black-Scholes option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option behaviors. We estimate the expected term based on the contractual term of the awards and employees' exercise and expected post-vesting termination behavior.
	We use the intrinsic method to account for restricted stock awards. The restricted stock awards are valued based on the closing stock price on the date of grant and amortized ratably over the life of the award.
	Additionally, we are required to disclose in our consolidated statements of cash flows the income tax effects resulting from share-based payment arrangements. We adopted the simplified method to calculate the beginning balance of the additional paid-in capital, or APIC, pool of excess tax benefits, and to determine the subsequent effect on the APIC pool and consolidated statements of cash flows of the tax effects of employee share-based compensation awards.
Stock Repurchases	'
	Stock Repurchases
	We account for common stock repurchases by charging the cost of shares acquired to the common stock account in the Consolidated Statements of Shareholders’ Equity.
Net Income Per Share	'
	Net Income Per Share
	Basic net income per share applicable to common shareholders is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalents shares, such as stock options and restricted stock outstanding during the period. Diluted earnings for our common shareholders per common stock considers the impact of potentially dilutive securities and excludes the impact of potential common shares related to our stock options and restricted stock in periods in which the option exercise or conversion price is greater than the average market price of our common stock during the period.
Segment Information	'
	Segment Information
	We have historically operated in one business segment. On January 18, 2013, we acquired 100% of the issued and outstanding shares of BioVectra Inc. We now manage our operations through two operating segments that are defined by our separate companies - Questcor Pharmaceuticals, Inc. and BioVectra. Each segment is operated as an independent business under its own management team, and has responsibility for its commercial activities, operations, and research and development activities related to its products. We intend to have BioVectra continue to operate independently under its existing management team for the foreseeable future.
	Questcor Pharmaceuticals is headquartered in Anaheim, California, and is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor Pharmaceuticals' primary product is Acthar. Questcor Pharmaceuticals currently generates substantially all of its net sales from the use of Acthar in connection with the following: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of certain rheumatology-related conditions, and the treatment of infantile spasms in infants and children under two years of age.
	BioVectra is located in Prince Edward Island, Canada, operating from three facilities. BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry. BioVectra manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents, and is our manufacturing partner for the API in our H.P. Acthar® Gel (repository corticotropin injection). BioVectra is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules.
	Segment results for net sales are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net income, which includes the negative impact of purchase price adjustments related to our January 18, 2013 acquisition of BioVectra, is the primary responsibility of segment operating management and therefore all activities remain in the segment in which incurred for performance assessment by our chief operating decision maker.
Subsequent Events	'
	Subsequent Events
	We evaluated subsequent events that have occurred after December 31, 2013, and through the issuance date, and determined that there were no events or transactions occurring during this reporting period that require recognition or disclosure in our consolidated financial statements.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date.

Organization_And_Summary_Of_Si2

Organization And Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Relative share of accounts receivable	'
	The relative share of our accounts receivable and gross product sales are as follows:



			Years Ended
			December 31,
	% of Accounts Receivable		2013			2012
	Specialty distributor		92	%		100	%
	Other customers		8	%		—	%
			100	%		100	%
Relative share of gross product sales	'


			Years Ended December 31,
	% of Gross Product Sales		2013			2012			2011
	Specialty distributor		95	%		100	%		100	%
	Other customers		5	%		—	%		—	%
			100	%		100	%		100	%
Net sales	'
	The following table sets forth our net sales for the years ended December 31, 2013, 2012 and 2011, respectively (in thousands):



			Years Ended December 31,
			2013				2012				2011
	Total pharmaceutical gross sales		$	825,710			$	582,097			$	268,827

	Sales reserves		64,363				72,805				50,658

	Total pharmaceutical net sales		761,347				509,292				218,169

	Total contract manufacturing net sales		37,582				—				—

	Total net sales		$	798,929			$	509,292			$	218,169

Sales-related reserves	'
	The following table summarizes the activity in the account for sales-related reserves for Medicaid rebates (in thousands):


			Years Ended December 31,
			2013				2012				2011
	Balance at January 1		$	33,921			$	29,874			$	17,384

	Actual Medicaid rebate payments for sales made in prior year		(22,891		)		(18,449		)		(9,104		)
	Actual Medicaid rebate payments for sales made in current year		(19,333		)		(35,709		)		(24,887		)
	Current Medicaid rebate provision for sales made in prior year		11,500				1,153				8

	Current Medicaid rebate provision for sales made in current year		27,784				57,052				46,473

	Balance at December 31		$	30,981			$	33,921			$	29,874

	Total Sales-related Reserves
	At December 31, 2013 and 2012 sales-related reserves included in the accompanying Consolidated Balance Sheets were as follows (in thousands):



			Years Ended December 31,
			2013				2012
	Medicaid rebates		$	30,981			$	33,921

	Other rebates, chargebacks and discounts		4,389				3,455

	Total		$	35,370			$	37,376

Net income per share, basic and diluted	'
	Diluted potential common shares resulting from the assumed exercise of outstanding stock options and restricted stock are determined based on the treasury stock method (in thousands, except per share amounts).



			Years Ended December 31,
			2013				2012				2011
	Net income applicable to common shareholders		$	292,609			$	197,675			$	79,591

	Shares used in computing net income per share applicable to common shareholders:
	Basic		58,616				60,243				62,498

	Effect of dilutive potential common shares:
	Stock options		2,375				2,744				3,497

	Restricted stock		456				58				15

	Diluted		61,447				63,045				66,010

	Net income per share applicable to common shareholders:
	Basic		$	4.99			$	3.28			$	1.27

	Diluted		$	4.76			$	3.14			$	1.21

Amounts excluded from the computation of diluted net income per share applicable to common shareholder	'
	The following table presents the amounts excluded from the computation of diluted net income per share applicable to common shareholders for the years ended December 31, 2013, 2012 and 2011, as the inclusion of these securities would have been anti-dilutive (in thousands):


			Years Ended December 31,
			2013			2012			2011
	Stock options		448			1,189			82

	Restricted stock awards		30			—			—

Schedule of earnings per share	'
	The following table sets forth the calculation of unallocated undistributed earnings, both basic and diluted, using the two-class method for amounts attributable to our common stock and our restricted stock awards (in thousands):


			Years Ended December 31,
			2013				2012				2011
	Net income applicable to common shareholders		$	292,609			$	197,675			$	79,591

	Less: Dividends		66,229				23,682				—

	Undistributed earnings		$	226,380			$	173,993			$	79,591


	Common stock undistributed earnings		$	221,278			$	173,325			$	79,591

	Unvested restricted stock award undistributed earnings		5,102				668				—

	Total undistributed earnings		$	226,380			$	173,993			$	79,591

Schedule of segment reporting information, by segment	'
	For the years ended December 31, 2013, 2012 and 2011, information regarding our net sales and net income for our operating segments is as follows (in millions):


		Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
	Net Sales
	For the year ended December 31, 2013	$	761,347		$	39,944		$	(2,362	)	$	798,929

	For the year ended December 31, 2012	$	509,292		$	—		$	—		$	509,292

	For the year ended December 31, 2011	$	218,169		$	—		$	—		$	218,169

	Net Income
	For the year ended December 31, 2013	$	293,999		$	(158	)	$	(1,232	)	$	292,609

	For the year ended December 31, 2012	$	197,675		$	—		$	—		$	197,675

	For the year ended December 31, 2011	$	79,591		$	—		$	—		$	79,591

Reconciliation of assets from segment to consolidated	'
	As of December 31, 2013, 2012 and 2011, information regarding total assets for our operating segments is as follows (in millions):


		Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
	Total Assets
	31-Dec-13	$	711,507		$	108,510		$	(83,663	)	$	736,354

	31-Dec-12	$	252,431		$	—		$	—		$	252,431

	31-Dec-11	$	275,808		$	—		$	—		$	275,808

Schedule of capital expenditures by operating segment	'
	As of December 31, 2013, 2012 and 2011, information regarding capital expenditures for our operating segments is as follows (in millions):


		Questcor Pharmaceuticals			BioVectra			Intersegment Eliminations			Consolidated
	Capital expenditures
	31-Dec-13	$	1,100		$	2,426		$	10		$	3,536

	31-Dec-12	$	1,065		$	—		$	—		$	1,065

	31-Dec-11	$	1,823		$	—		$	—		$	1,823

Schedule of net sales by geographic location	'
	The basis for determining net sales is the geographic location of the customer (in thousands):


		December 31,
		2013			2012			2011
	Net Sales
	North America (1)	$	778,859		$	509,292		$	218,169

	Europe	13,780			—			—

	Asia	6,248			—			—

	Other	42			—			—

	Total net sales	$	798,929		$	509,292		$	218,169

	(1) Predominately located in the United States and Canada.

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table reflects the fair value of consideration transferred at the acquisition date (in thousands):



	Allocation of Purchase Price:
	Current assets excluding inventory	$	11,691

	Inventory	11,774

	Property and equipment	35,221

	Other non-current assets	1,708

	Current deferred tax asset	141

	Intangibles	35,581

	Goodwill	21,914

	Current liabilities	(6,451		)
	Non-current liabilities, excluding long-term debt	(1,994		)
	Non-current deferred tax liability	(12,012		)
	Long-term debt	(16,875		)
	Total net assets acquired	$	80,698


	Cash consideration paid to BioVectra shareholders	$	50,315

	Estimated fair value of contingent consideration	30,383

	Total purchase consideration	$	80,698

Business Acquisition, Pro Forma Information	'
	Pro forma adjustments are tax-effected at the applicable statutory tax rates.


		Year Ended December 31,
		2013			2012
	Net sales	$	800,788		$	537,511

	Net income	$	301,837		$	193,389

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'
Inventories, net of allowances	'
	We state inventories, net of allowances, at the lower of cost (first-in, first-to-expire) or market. For our production materials and supplies, work-in-process and finished goods at our contract manufacturer, cost is determined on an average cost basis. Inventories, net of allowances, at December 31, 2013 and 2012 consist of the following (in thousands):



			Years Ended December 31,
			2013			2012
	Raw materials		$	9,835		$	9,271

	Work-in-process		2,194			—

	Intermediates		1,572			—

	Finished goods		4,096			690

			17,697			9,961

	Less: Reserve for obsolescence		(1,329		)	(52		)
			$	16,368		$	9,909

Property and Equipment	'
	Equipment, building, land and leasehold improvements and related accumulated depreciation and amortization are as follows (in thousands):



			Years Ended December 31,
			2013			2012
	Equipment (including manufacturing, laboratory and office)		$	26,237		$	3,466

	Building		12,015			—

	Land and land improvements		406			—

	Leasehold improvements		1,446			1,349

			40,104			4,815

	Less accumulated depreciation and amortization		(8,371		)	(2,742		)
			$	31,733		$	2,073

Schedule of Long-term Debt Instruments	'
	The term loan has an interest rate of 4%, is due in full by February 2022 and is secured by certain of our BioVectra assets. Under the supply agreement, the customer agreed to reimburse BioVectra (such reimbursement is recorded to net sales) for the quarterly financing payments of C$450,743 during the term of the loan.


		December 31, 2013
	4% Term Loan, due February 2022, payable in quarterly installments of C$450,743 including principal and interest	$	12,090

	Less: Current Portion	1,221

	Funded long-term debt, less current portion	$	10,869

	Long-term debt
	Our subsidiary, BioVectra, has a 2.85% term loan. The loan is payable monthly and is due April 2016. The loan is secured with BioVectra accounts receivable and inventory.


		December 31, 2013
	2.85% Term Loan, due April 2016, payable in monthly installments of C$48,170 including principal and interest	$	3,573

	Less: Current Portion	444

	Long-term debt, less current portion	$	3,129

Schedule of Maturities of Debt	'
	Debt maturity schedule


	2014	$	1,665

	2015	1,727

	2016	3,994

	2017	1,375

	2018	1,431

	Thereafter	5,471

	Total	$	15,663

ShortTerm_Investments_And_Fair1

Short-Term Investments And Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Short-Term Investments And Fair Value Measurements [Abstract]	'
Summary of cash equivalents and short-term investments	'
	A summary of cash equivalents and short-term investments, classified as available-for-sale, and carried at fair value is as follows (in thousands):


	December 31, 2013		Amortized				Gross			Gross			Estimated
			Cost				Unrealized			Unrealized			Fair
							Gain			(Loss)			Value
	Cash equivalents		$	13,351			$	—		$	—		$	13,351

	Short-term investments:
	Corporate bonds		$	45,190			$	11		$	(14	)	$	45,187

	U.S. Government-sponsored enterprises		14,539				3			(4		)	14,538

	Municipal bonds		9,438				4			(1		)	9,441

			$	69,167			$	18		$	(19	)	$	69,166

	December 31, 2012
	Cash equivalents		$	7,740			$	—		$	—		$	7,740

	Short-term investments:
	Certificates of deposit		$	720			$	2		$	—		$	722

	Corporate Bonds		47,857				29			(8		)	47,878

	Government-sponsored enterprises		24,699				13			—			24,712

	Municipal bonds		1,395				1			(3		)	1,393

			$	74,671			$	45		$	(11	)	$	74,705

Amortized cost and fair value of available-for-sale securities	'
	The amortized cost and fair value of available-for-sale securities at December 31, 2013, by contractual maturity, are as follows (in thousands):


			Amortized				Estimated Fair
			Cost				Value
	Due in one year or less		$	31,717			$	31,721

	Due after one through two years		37,450				37,445

	Total available-for-sale securities		$	69,167			$	69,166

Available-for-sale securities in an unrealized loss position, not deemed to be other-than-temporarily impaired	'
	As of December 31, 2013, we had the following available-for-sale securities that were in an unrealized loss position but were not deemed to be other-than-temporarily impaired (in thousands):


			Less Than 12 Months							12 Months or Greater
			Gross Unrealized Losses				Estimated Fair Value			Gross Unrealized Losses			Estimated Fair Value
	Corporate bonds		$	(4	)		$	9,809		$	(10	)	$	8,932

	U.S. Government-sponsored enterprises		—				—			(4		)	9,033

	Municipal bonds		—				1,336			(1		)	1,473

	Total		$	(4	)		$	11,145		$	(15	)	$	19,438

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	As of December 31, 2013 and 2012, assets and liabilities measured at fair value on a recurring basis are summarized below (in thousands):



				Basis of Fair Value Measurements
				Balance at
	Balance Sheet Classification			December 31,				Level 1			Level 2			Level 3
				2013
	Cash and cash equivalents	Cash and cash equivalents		$	13,351			$	5,260		$	8,091		$	—

	Short-term investments	Corporate bonds		45,187				—			45,187			—

	Short-term investments	Government-sponsored enterprises		14,538				—			14,538			—

	Short-term investments	Municipal bonds		9,441				—			9,441			—

		Total assets		$	82,517			$	5,260		$	77,257		$	—


	Current liabilities	Current portion of contingent consideration in conjunction with acquisition of BioVectra		$	4,238			$	—		$	—		$	4,238

	Current liabilities	Current portion of contingent consideration in conjunction with acquisition of Synacthen		25,000				—			—			25,000

	Non-current liabilities	Contingent consideration in conjunction with acquisition of BioVectra		33,224				—			—			33,224

	Non-current liabilities	Contingent consideration in conjunction with acquisition of Synacthen		115,066				—			—			115,066

		Total liabilities		$	177,528			$	—		$	—		$	177,528


				December 31,				Level 1			Level 2			Level 3
				2012
	Cash and cash equivalents	Cash and cash equivalents		$	7,740			$	7,242		$	498		$	—

	Short-term investments	Certificates of deposit		722				—			722			—

	Short-term investments	Corporate bonds		47,878				—			47,878			—

	Short-term investments	Government-sponsored enterprises		24,712				—			24,712			—

	Short-term investments	Municipal bonds		1,393				—			1,393			—

		Total assets		$	82,445			$	7,242		$	75,203		$	—

Fair Value Inputs, Liabilities, Quantitative Information	'
	The following table presents the fair value, valuation technique and related unobservable input for the Level 3 measurements:


		Fair Value			Valuation Technique	Unobservable Input	Rate
	Contingent consideration in conjunction with the acquisition of Bio Vectra estimate	$	37,462		Probability weighted	Discount rate	5%
					discounted future cash flows
	Contingent consideration in conjunction with the acquisition of Synacthen estimate	$	140,066		Probability weighted	Discount rate	5%
					discounted future cash flows
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	'
	The following table represents a roll forward of the fair value of Level 3 instruments, comprised solely of the contingent consideration, including the current portion of the contingent consideration:


			December 31, 2013
	Balance at beginning of period		$	—

	Amounts acquired or issued		167,046

	Change due to compensation expense		1,893

	Change due to time value of money		4,528

	Change due to foreign currency translation adjustment		(2,368		)
	Changes in fair value		6,429

	Balance at end of period		$	177,528

Goodwill_Intangibles_and_Purch1

Goodwill, Intangibles and Purchased Technology (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill Acquired with the Acquisition of BioVectra	'
	Goodwill and intangibles acquired in conjunction with the acquisition of BioVectra, consists of the following (in thousands):


			December 31,
			2013
	Acquired intangibles		$	33,186

	Less accumulated amortization		(3,055		)
	Acquired intangibles, net		$	30,131

	Goodwill		$	20,464

Goodwill	'
	The following table summarizes the changes in the carrying amount of goodwill (in thousands):


	Balance at December 31, 2012		$	—

	Goodwill resulting from the acquisition of BioVectra		21,914

	Currency translation		(1,450		)
	Balance at December 31, 2013		$	20,464

	The following table provides a rollforward of goodwill by country (in thousands):


		December 31,			Additions from Purchase Accounting			Currency Translation			December 31,
		2012									2013
	United States	$	—		$	—		$	—		$	—

	Canada	—			21,914			(1,450		)	20,464

	Total	$	—		$	21,914		$	(1,450	)	$	20,464

Rollforward of intangibles	'
	The following table provides a rollforward of the intangibles (in thousands):


		December 31,
		2013
		Gross Book Value			Accumulated Amortization			Currency Translation			Net Book Value
	Trademark	$	8,151		$	—		$	(577	)	$	7,574

	Patent	58			(15		)	(3		)	$	40

	Contracted customer relationships	17,208			(1,578		)	(1,154		)	$	14,476

	Non-contracted customer relationships	10,164			(1,462		)	(661		)	$	8,041

	Total acquired intangibles	$	35,581		$	(3,055	)	$	(2,395	)	$	30,131

Changes in Intangibles	'
	The following table summarizes the changes in the carrying amount of intangibles (in thousands):


	Balance at December 31, 2012		$	—

	Intangibles resulting from the acquisition of BioVectra		35,581

	Amortization expense		(3,055		)
	Currency translation		(2,395		)
	Balance at December 31, 2013		$	30,131

Schedule of Finite-Lived Intangible Assets	'
	Intangibles acquired in conjunction with the acquisition of Synacthen, consists of the following (in thousands):


			December 31,				December 31,
			2013				2012
	In process R&D asset		$	196,663			$	—

	Less accumulated amortization		(5,212		)		—

	In process R&D asset, net		$	191,451			$	—

Preferred_Stock_And_Shareholde1

Preferred Stock And Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Employee stock purchase plan activity	'
	ESPP activity during 2013 was as follows:


		Number of		Weighted-
		Shares		Average Fair
				Value
	Available at December 31, 2012	682,080

	Purchases	(137,472	)	$	29.49

	Shares added to the Plan	—

	Available at December 31, 2013	544,608

Schedule of Valuation Assumptions	'


		Years Ended December 31,
		2013		2012			2011
	Weighted average volatility	52	%	110	%		53	%
	Risk-free interest rate	0.1	%	0.1	%		0.1	%
	Expected term (in years)	0.25		0.25			0.25

	Expected dividend yield	2.4	%	1.4	%		—	%
Summary of stock option activity	'
	A summary of our stock option activity and related information during 2012 follows:


		Stock		Weighted-				Weighted-		Aggregate
		Options		Average				Average		Intrinsic Value
				Exercise				Remaining
				Price				Contractual
								Term
								(In years)
	Outstanding at December 31, 2012	6,446,618		$	16.52

	Granted	426,896		35.66

	Exercised	(1,692,920	)	9.44

	Forfeited or expired	(118,489	)	30.16

	Outstanding at December 31, 2013	5,062,105		$	20.18			6.98		$	173,920,567

	Options vested and expected to vest at December 31, 2013	4,993,859		$	19.99			6.96		$	172,493,803

	Exercisable at December 31, 2013	3,442,547		$	15.02			6.38		$	135,750,172

Restricted stock activity	'
	Restricted stock activity during 2013 was as follows:


		Number		Weighted-
		of Shares		Average Fair
				Value
	Non-vested shares at December 31, 2012	789,479		$	26.42

	Granted	829,899		$	34.14

	Released	(205,181	)	$	26.5

	Forfeited or expired	(51,033	)	$	28.34

	Non-vested shares at December 31, 2013	1,363,164		$	30.99

Schedule of Restricted Stock Activity	'
	Restricted stock unit activity during 2013 was as follows:


		Number		Weighted-				Weighted-		Aggregate
		of Shares		Average Fair Value				Average		Intrinsic Value
								Remaining
								Contractual
								Term
	Outstanding at December 31, 2012	—		$	—

	Granted	10,515		$	51.69

	Released	—		$	—

	Forfeited or expired	—		$	—

	Outstanding at December 31, 2013	10,515		$	—			2.17		$	572,541.75

	Vested and expected to vest at December 31, 2013	9,622		$	—			2.12		$	523,915.46

	Exercisable at December 31, 2013	—		$	—			0		$	—

Weighted average fair value of equity instruments	'
	The weighted average fair value of equity instruments granted during 2013, 2012 and 2011 was as follows:


		Weighted Average Fair Value
		2013			2012				2011
	Stock options	$	35.66		$	36.16			$	16.89

	ESPP Purchases	$	29.49		$	28.91			$	14.98

	Restricted Stock Awards	$	34.14		$	26.86			$	27.28

	Restricted Stock Units	$	51.69		$	—			$	—

Stock option valuation assumption	'
	The weighted average assumptions used for the years ended December 31, 2013, 2012 and 2011 and the resulting estimates of weighted average fair value per share of options granted during those periods are as follows:



		Years Ended December 31,
		2013		2012			2011
	Volatility	71	%	72	%		61	%
	Interest rate	0.4-0.8		0.3-0.5			0.5-2.4

	Forfeiture rate	4.05	%	4.99	%		7.61	%
	Expected term (in years)	3.6		3.6			3.4

	Expected dividend yield	2.6	%	3.2	%		—	%
Share-based compensation expense	'
	Share-based compensation expense related to employees and non-employee members of the Board of Directors has been included in the accompanying Consolidated Statements of Income for the years ended December 31, 2013, 2012 and 2011 as follows (in thousands):


		Years Ended December 31,
		2013			2012				2011
	Selling and marketing	$	10,897		$	5,360			$	4,236

	General and administrative	12,302			7,467				1,884

	Research and development	5,554			2,965				1,206

	Total share-based compensation expense	$	28,753		$	15,792			$	7,326

Indemnifications_Commitments_A1

Indemnifications, Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future annual minimum payments under operating leases	'
	Future annual minimum payments under operating leases are as follows (in thousands):



	Years Ending December 31,
	2014	$	5,651

	2015	4,173

	2016	2,123

	2017	1,085

	2018	291

	Thereafter	331

	Total	$	13,654

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax	'
	Income before income taxes is attributed to the following geographic locations for the years ended December 31, 2013, 2012 and 2011 (in thousands):


		Years Ended December 31,
		2013				2012				2011
	Federal	$	449,285			$	297,230			$	113,745

	Foreign	(9,745		)		—				—

	Income before income taxes	$	439,540			$	297,230			$	113,745

Components of the income tax expense	'
	The components of the income tax expense are as follows (in thousands):


		Years Ended December 31,
		2013				2012				2011
	Current:
	Federal	$	158,914			$	97,267			$	38,575

	State	1,615				2,047				475

	Foreign	1,251				—				—

		161,780				99,314				39,050

	Deferred:
	Federal	(13,026		)		344				(4,782		)

	State	(64		)		(103		)		(114		)
	Foreign	(1,759		)		—				—

		(14,849		)		241				(4,896		)

	Total income tax expense	$	146,931			$	99,555			$	34,154

Reconciliation between U.S. statutory tax rate and effective tax rate	'
	A reconciliation between the U.S. statutory tax rate and our effective tax rate is as follows:


		Years Ended December 31,
		2013			2012			2011
	Tax at U.S. statutory rate	35	%		35	%		35	%
	State income taxes, net	0.4	%		0.7	%		0.2	%
	Change in valuation allowance	—	%		—	%		—	%
	Orphan drug tax credit	—	%		—	%		(2.1	)%
	Foreign rate differential	0.7	%		—	%		—	%
	Other	(2.7	)%		(2.2	)%		(3.1	)%
	Effective tax rate	33.4	%		33.5	%		30	%
Significant components of deferred tax assets	'
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amount used for income tax purposes, as well as net operating loss and tax credit carryforwards. Significant components of our deferred tax assets and liabilities are as follows (in thousands):


		Years Ended December 31,
		2013				2012
	Deferred tax assets:
	Net operating loss carryforwards	$	1,879			$	2,117

	Research and development credits	68				92

	Sales-related reserves	4,656				5,803

	Stock-based compensation	12,575				8,006

	Intangible asset	1,121				—

	Other, net	12,240				2,219

	Total deferred tax assets	32,539				18,237

	Valuation allowance	(920		)		(981		)
		31,619				17,256

	Deferred tax liabilities:
	Capital assets	(10,569		)		$	—

	Net deferred taxes	$	21,050			$	17,256

Reconciliation of unrecognized tax benefits	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):


		Years Ended
		December 31,
		2013				2012
	Balance at beginning of year	$	1,223			$	1,274

	Increase / (decrease) of unrecognized tax benefits taken in prior years	377				(437		)

	Increase of unrecognized tax benefits related to current year	(319		)		386

	Balance at end of year	$	1,281			$	1,223

Quarterly_Results_Of_Operation1

Quarterly Results Of Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	QUARTERLY FINANCIAL INFORMATION (UNAUDITED)



			Quarter Ended
			12/31/13		9/30/13		6/30/13		3/31/13
	Net sales		$	242,881	$	236,346	$	184,573	$	135,129

	Cost of sales		20,921		20,034		17,221		16,189

	Income tax expense		48,839		45,668		33,969		18,455

	Net income		89,981		94,441		69,123		39,064

	Comprehensive income		88,430		95,372		67,644		37,870

	Net income per share applicable to common shareholders (1):
	Basic		$	1.51	$	1.6	$	1.17	$	0.68

	Diluted		$	1.44	$	1.52	$	1.12	$	0.65

	Dividend declared per common share		$	0.6	$	—	$	0.25	$	0.25


			Quarter Ended
			12/31/12		9/30/12		6/30/12		3/31/12
	Net sales		$	160,533	$	140,339	$	112,452	$	95,968

	Cost of sales		9,157		7,499		6,379		5,520

	Income tax expense		32,987		27,836		19,724		19,008

	Net income		61,940		55,687		41,505		38,543

	Comprehensive income		61,926		55,700		41,491		38,634

	Net income per share applicable to common shareholders (1):
	Basic		$	1.07	$	0.95	$	0.68	$	0.61

	Diluted		$	1.03	$	0.91	$	0.65	$	0.58

	Dividend declared per common share		$	0.2	$	0.2	$	—	$	—




	(1	)	Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Organization_And_Summary_Of_Si3

Organization And Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	1 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2012
		pharmacy
		indication
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Number of indications that are approved for treatment	'	19	'	'
Impairment of goodwill and intangibles	$700,000	'	$299,000	'
Deferred tax liability not recognized	'	1,281,000	1,274,000	1,223,000
Unrecognized tax benefits, income tax penalties and interest accrued	'	78,000	'	106,000
Unrecognized tax benefits, expected decrease as a result of settlement with IRS	'	500,000	'	'
Number of specialty pharmacies that distribute	'	12	'	'
Unrecognized compensation cost, unvested stock options	'	20,400,000	'	'
Weighted average vesting period, years	'	'2 years 2 months 1 day	'	'
Restricted Stock and Restricted Stock Units [Member] \| 2006 Equity Incentive Award Plan [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Unrecognized compensation cost	'	$25,800,000	'	'
Acthar [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Maximum treatment age of infantile spasms	'	'2 years	'	'
Shelf life from the date of manufacture	'	'18 months	'	'
Maximum [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Days after quarter, rebate invoices received	'	'90 days	'	'
Minimum [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Days after quarter, rebate invoices received	'	'60 days	'	'

Organization_And_Summary_Of_Si4

Organization And Summary Of Significant Accounting Policies (Concentration Risk) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Concentration Risk [Line Items]	'	'	'
Insurance coverage per depositor on all non-interest bearing cash balances	250,000	'	'
Accounts Receivable [Member] \| Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	100.00%	100.00%	'
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Specialty distributor	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	92.00%	100.00%	'
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Other customers	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	8.00%	0.00%	'
Sales [Member] \| Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	100.00%	100.00%	100.00%
Sales [Member] \| Customer Concentration Risk [Member] \| Specialty distributor	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	95.00%	100.00%	100.00%
Sales [Member] \| Customer Concentration Risk [Member] \| Other customers	'	'	'
Concentration Risk [Line Items]	'	'	'
Credit to customer as a percentage	5.00%	0.00%	0.00%

Organization_And_Summary_Of_Si5

Organization And Summary Of Significant Accounting Policies (Net Sales) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total pharmaceutical gross sales	'	'	'	'	'	'	'	'	$825,710	$582,097	$268,827
Sales reserves	'	'	'	'	'	'	'	'	64,363	72,805	50,658
Pharmaceutical net sales	'	'	'	'	'	'	'	'	761,347	509,292	218,169
Contract manufacturing net sales	'	'	'	'	'	'	'	'	37,582	0	0
Total net sales	$242,881	$236,346	$184,573	$135,129	$160,533	$140,339	$112,452	$95,968	$798,929	$509,292	$218,169

Organization_And_Summary_Of_Si6

Organization And Summary Of Significant Accounting Policies (Sales-Related Reserves) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Sales-Related Reserves [Line Items]	'	'	'
Sales-related reserves	$35,370	$37,376	'
Medicaid [Member]	'	'	'
Sales-Related Reserves [Line Items]	'	'	'
Beginning balance	33,921	29,874	17,384
Actual Medicaid rebate payments for sales made in prior year	-22,891	-18,449	-9,104
Actual Medicaid rebate payments for sales made in current year	-19,333	-35,709	-24,887
Current Medicaid rebate provision for sales made in prior year	11,500	1,153	8
Current Medicaid rebate provision for sales made in current year	27,784	57,052	46,473
Ending balance	30,981	33,921	29,874
Sales-related reserves	30,981	33,921	'
Other rebates, chargebacks and discounts	'	'	'
Sales-Related Reserves [Line Items]	'	'	'
Sales-related reserves	$4,389	$3,455	'

Organization_And_Summary_Of_Si7

Organization And Summary Of Significant Accounting Policies (Net Income Per Share, Basic And Diluted) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Net income applicable to common shareholders

$89,981

$94,441

$69,123

$39,064

$61,940

$55,687

$41,505

$38,543

$292,609

$197,675

$79,591

Basic shares used in computing net income per share applicable to common shareholders

58,616

60,243

62,498

Effect of dilutive potential common shares, stock options shares used in computing net income per share applicable to common shareholders

2,375

2,744

3,497

Effect of dilutive potential common shares, restricted stock shares used in computing net income per share applicable to common shareholders

456

Diluted shares used in computing net income per share applicable to common shareholders

61,447

63,045

66,010

Earnings per share basic, applicable to common shareholders

$1.51

[1]

$1.60

[1]

$1.17

[1]

$0.68

[1]

$1.07

[1]

$0.95

[1]

$0.68

[1]

$0.61

[1]

$4.99

$3.28

$1.27

Earnings per share diluted, applicable to common shareholders

$1.44

[1]

$1.52

[1]

$1.12

[1]

$0.65

[1]

$1.03

[1]

$0.91

[1]

$0.65

[1]

$0.58

[1]

$4.76

$3.14

$1.21

[1]

Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Organization_And_Summary_Of_Si8

Organization And Summary Of Significant Accounting Policies (Antidilutive Securities) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock options	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from computation of diluted net income per share	448	1,189	82
Restricted stock awards	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Securities excluded from computation of diluted net income per share	30	0	0

Organization_And_Summary_Of_Si9

Organization And Summary Of Significant Accounting Policies (Unallocated Undistributed Earnings) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income	$89,981	$94,441	$69,123	$39,064	$61,940	$55,687	$41,505	$38,543	$292,609	$197,675	$79,591
Less: Dividends	'	'	'	'	'	'	'	'	66,229	23,682	0
Undistributed earnings	'	'	'	'	'	'	'	'	226,380	173,993	79,591
Common stock undistributed earnings	'	'	'	'	'	'	'	'	221,278	173,325	79,591
Unvested restricted stock award undistributed earnings	'	'	'	'	'	'	'	'	5,102	668	0
Total undistributed earnings	'	'	'	'	'	'	'	'	$226,380	$173,993	$79,591

Recovered_Sheet1

Organization And Summary Of Significant Accounting Policies (Segment Reporting) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 18, 2013

North America [Member]

Europe [Member]

Asia [Member]

Other Geographical Region [Member]

Questcor [Member]

BioVectra [Member]

Intersegment Eliminations [Member]

BioVectra [Member]

Segment Reporting Information [Line Items]

Percentage of voting interest acquired

100.00%

Total net sales

$242,881

$236,346

$184,573

$135,129

$160,533

$140,339

$112,452

$95,968

$798,929

$509,292

$218,169

$778,859

[1]

$509,292

[1]

$218,169

[1]

$13,780

$6,248

$42

$761,347

$509,292

$218,169

$39,944

($2,362)

Net income

89,981

94,441

69,123

39,064

61,940

55,687

41,505

38,543

292,609

197,675

79,591

293,999

197,675

79,591

-158

-1,232

Assets

736,354

252,431

736,354

252,431

275,808

711,507

252,431

275,808

108,510

-83,663

Capital expenditures

$3,536

$1,065

$1,823

$1,100

$1,065

$1,823

$2,426

$10

[1]

Predominately located in the United States and Canada.

Acquisitions_Synacthen_Details

Acquisitions (Synacthen) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Jun. 11, 2013	Dec. 31, 2013	Jun. 11, 2013
			Synacthen [Member]	Synacthen [Member]	Synacthen [Member]
					Maximum [Member]
Business Acquisition [Line Items]	'	'	'	'	'
Upfront consideration paid	'	'	$60,000,000	'	'
Annual cash payments	'	'	25,000,000	'	'
Annual payments secured by a letter of credit	'	'	75,000,000	'	'
Total payment	'	'	'	'	300,000,000
Acquired intangibles, net	30,131,000	0	'	191,500,000	'
Contingent consideration estimate	'	'	'	$140,100,000	'

Acquisitions_BioVectra_Details

Acquisitions (BioVectra) (Details)	12 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 18, 2013	Dec. 31, 2013	Dec. 31, 2013	Jan. 18, 2013
	USD ($)	USD ($)	USD ($)	BioVectra [Member]	BioVectra [Member]	BioVectra [Member]	BioVectra [Member]
				USD ($)	USD ($)	CAD	CAD
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Percentage of voting interest acquired	'	'	'	'	'	'	100.00%
Total cash paid for acquisition of BioVectra	$50,803,000	'	'	$50,315,000	'	'	'
Maximum additional cash consideration	'	'	'	'	37,500,000	'	50,000,000
Number of years financial results are based on	'	'	'	'3 years	'	'	'
Estimated fair value of contingent consideration	30,383,000	'	'	30,383,000	'	'	'
Changes in fair value of contingent consideration	6,429,000	0	0	'	'	5,000,000	'
Current portion of contingent consideration	4,238,000	0	'	'	4,200,000	'	'
Acquisition-related expenses	'	'	'	'	$300,000	'	'

Acquisitions_Purchase_Price_Al

Acquisitions (Purchase Price Allocation) (Details) (USD $)	12 Months Ended		0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jan. 18, 2013	Dec. 31, 2013
	Dec. 31, 2013	Dec. 31, 2012	BioVectra [Member]	BioVectra [Member]
Business Acquisition [Line Items]	'	'	'	'
Current assets excluding inventory	'	'	$11,691	'
Inventory	'	'	11,774	'
Property and equipment	'	'	35,221	'
Other non-current assets	'	'	1,708	'
Current deferred tax asset	'	'	141	'
Intangibles	'	'	35,581	'
Goodwill	20,464	0	21,914	20,464
Current liabilities	'	'	-6,451	'
Non-current liabilities, excluding long-term debt	'	'	-1,994	'
Non-current deferred tax liability	'	'	-12,012	'
Long-term debt	'	'	-16,875	'
Total net assets acquired	'	'	80,698	'
Total cash paid for acquisition of BioVectra	50,803	'	50,315	'
Estimated fair value of contingent consideration	30,383	'	30,383	'
Total purchase consideration	'	'	$80,698	'

Acquisitions_Pro_Forma_Financi

Acquisitions (Pro Forma Financial Information) (Details) (BioVectra [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
BioVectra [Member]	'	'
Business Acquisition [Line Items]	'	'
Net sales	$800,788	$537,511
Net income	$301,837	$193,389

Balance_Sheet_Details_Inventor

Balance Sheet Details (Inventories, Net Of Allowances) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$9,835	$9,271
Work-in-process	2,194	0
Intermediates	1,572	0
Finished goods	4,096	690
Inventory, Gross	17,697	9,961
Less: Reserve for obsolescence	-1,329	-52
Total inventory	16,368	9,909
BioVectra [Member]	'	'
Inventory [Line Items]	'	'
Total inventory	$6,700	'

Balance_Sheet_Details_Property

Balance Sheet Details (Property And Equipment) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment	$40,104,000	$4,815,000	'
Less accumulated depreciation and amortization	-8,371,000	-2,742,000	'
Total	31,733,000	2,073,000	'
Total depreciation and amortization expense	5,900,000	900,000	700,000
Equipment (including manufacturing, laboratory and office)	'	'	'
Property and equipment	26,237,000	3,466,000	'
Building	'	'	'
Property and equipment	12,015,000	0	'
Land and land improvements	'	'	'
Property and equipment	406,000	0	'
Leasehold improvements	'	'	'
Property and equipment	1,446,000	1,349,000	'
BioVectra [Member]	'	'	'
Property and equipment	29,400,000	'	'
Total depreciation and amortization expense	$5,100,000	'	'

Balance_Sheet_Details_Longterm

Balance Sheet Details (Long-term Debt) (Details)	12 Months Ended			12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	CAD	USD ($)	Term Loan [Member]	Term Loan [Member]	Term Loan [Member]	Term Loan [Member]
				Term Loan Due February 2022	Term Loan Due February 2022	Term Loan Due April 2016	Term Loan Due April 2016
				CAD	USD ($)	CAD	USD ($)
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Period to supply pharmaceutical product	'10 years	'10 years	'	'	'	'	'
Estimated facility construction cost	'	14,800,000	'	'	'	'	'
Interest rate	'	'	'	'	4.00%	'	2.85%
Installments	'	'	'	450,743	'	48,170	'
Funded long-term debt	15,663,000	'	'	'	12,090,000	'	3,573,000
Current portion of long-term debt	1,665,000	'	0	'	1,221,000	'	444,000
Long-term debt, less current portion	13,998,000	'	0	'	10,869,000	'	3,129,000
Debt maturities	'	'	'	'	'	'	'
2014	1,665,000	'	'	'	'	'	'
2015	1,727,000	'	'	'	'	'	'
2016	3,994,000	'	'	'	'	'	'
2017	1,375,000	'	'	'	'	'	'
2018	1,431,000	'	'	'	'	'	'
Thereafter	5,471,000	'	'	'	'	'	'
Long-term debt	$15,663,000	'	'	'	$12,090,000	'	$3,573,000

ShortTerm_Investments_And_Fair2

Short-Term Investments And Fair Value Measurements (Summary Of Cash Equivalents And Short-Term Investments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$69,167	$74,671
Gross Unrealized Gain	18	45
Gross Unrealized (Loss)	-19	-11
Estimated Fair Value	69,166	74,705
Cash equivalents	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	13,351	7,740
Gross Unrealized Gain	0	0
Gross Unrealized (Loss)	0	0
Estimated Fair Value	13,351	7,740
Certificates of deposit	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	'	720
Gross Unrealized Gain	'	2
Gross Unrealized (Loss)	'	0
Estimated Fair Value	'	722
Corporate bonds	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	45,190	47,857
Gross Unrealized Gain	11	29
Gross Unrealized (Loss)	-14	-8
Estimated Fair Value	45,187	47,878
U.S. Government-sponsored enterprises	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	14,539	24,699
Gross Unrealized Gain	3	13
Gross Unrealized (Loss)	-4	0
Estimated Fair Value	14,538	24,712
Municipal bonds	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	9,438	1,395
Gross Unrealized Gain	4	1
Gross Unrealized (Loss)	-1	-3
Estimated Fair Value	$9,441	$1,393

ShortTerm_Investments_And_Fair3

Short-Term Investments And Fair Value Measurements (Amortized Cost And Fair Value Of Available-For-Sale Securities) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Short-Term Investments And Fair Value Measurements [Abstract]	'
Due in one year or less, Amortized Cost	$31,717
Due after one through two years, Amortized Cost	37,450
Total available-for-sale securities, Amortized Cost	69,167
Due in one year or less, Estimated Fair Value	31,721
Due after one through two years, Estimated Fair Value	37,445
Total available-for-sale securities, Estimated Fair Value	$69,166
Average contractual maturity of short term investments, in months	'13 months

ShortTerm_Investments_And_Fair4

Short-Term Investments And Fair Value Measurements (Available-For-Sale Securities In An Unrealized Loss Position, Not Deemed To Be Other-Than-Temporarily Impaired) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'
Gross Unrealized Losses, Less Than 12 Months	($4)
Estimated Fair Value, Less Than 12 Months	11,145
Gross Unrealized Losses, 12 Months or Greater	-15
Estimated Fair Value, 12 Months or Greater	19,438
Corporate bonds	'
Schedule of Available-for-sale Securities [Line Items]	'
Gross Unrealized Losses, Less Than 12 Months	-4
Estimated Fair Value, Less Than 12 Months	9,809
Gross Unrealized Losses, 12 Months or Greater	-10
Estimated Fair Value, 12 Months or Greater	8,932
U.S. Government-sponsored enterprises	'
Schedule of Available-for-sale Securities [Line Items]	'
Gross Unrealized Losses, Less Than 12 Months	0
Estimated Fair Value, Less Than 12 Months	0
Gross Unrealized Losses, 12 Months or Greater	-4
Estimated Fair Value, 12 Months or Greater	9,033
Municipal bonds	'
Schedule of Available-for-sale Securities [Line Items]	'
Gross Unrealized Losses, Less Than 12 Months	0
Estimated Fair Value, Less Than 12 Months	1,336
Gross Unrealized Losses, 12 Months or Greater	-1
Estimated Fair Value, 12 Months or Greater	$1,473

ShortTerm_Investments_And_Fair5

Short-Term Investments And Fair Value Measurements (Assets Measured At Fair Value On A Recurring Basis) (Details) (USD $)

1 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

BioVectra [Member]

Synacthen [Member]

Income Approach Valuation Technique [Member]

Level 1

Level 2

Level 3

Cash and cash equivalents

Certificates of deposit

Corporate bonds

Government-sponsored enterprises

Municipal bonds

BioVectra [Member]

Synacthen [Member]

BioVectra [Member]

Synacthen [Member]

BioVectra [Member]

Synacthen [Member]

BioVectra [Member]

Synacthen [Member]

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets

$82,517,000

$82,445,000

$5,260,000

$7,242,000

$77,257,000

$75,203,000

$13,351,000

$7,740,000

$5,260,000

$7,242,000

$8,091,000

$498,000

$722,000

$45,187,000

$47,878,000

$45,187,000

$47,878,000

$14,538,000

$24,712,000

$14,538,000

$24,712,000

$9,441,000

$1,393,000

$9,441,000

$1,393,000

Current portion of contingent consideration in conjunction with acquisition

4,238,000

25,000,000

4,238,000

25,000,000

Contingent consideration in conjunction with acquisition

33,224,000

115,066,000

33,224,000

115,066,000

Liabilities

177,528,000

Fair Value Inputs [Abstract]

Contingent consideration estimate

140,100,000

37,462,000

140,066,000

Discount rate

5.00%

Fair Value of Level 3 Instruments [Roll Forward]

Balance at beginning of period

Amounts acquired or issued

167,046,000

Change due to compensation expense

1,893,000

Change due to time value of money

4,528,000

Change due to foreign currency translation adjustment

-2,368,000

Changes in fair value

6,429,000

Balance at end of period

177,528,000

Impairment of goodwill and intangibles

700,000

299,000

Agreed upon purchase price for the Purchased Technology

$700,000

Goodwill_Intangibles_and_Purch2

Goodwill, Intangibles and Purchased Technology (Goodwill and Intangibles) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jan. 18, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	BioVectra [Member]	BioVectra [Member]
Schedule of Intangible Assets, Including Goodwill [Line Items]	'	'	'	'
Acquired intangibles	$35,581	'	$33,186	'
Accumulated Amortization	-3,055	'	-3,055	'
Acquired intangibles, net	30,131	0	30,131	'
Goodwill	$20,464	$0	$20,464	$21,914

Goodwill_Intangibles_and_Purch3

Goodwill, Intangibles and Purchased Technology (Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Jan. 18, 2013
	Dec. 31, 2013	United States [Member]	Canada [Member]	BioVectra [Member]	BioVectra [Member]
Goodwill [Roll Forward]	'	'	'	'	'
Beginning balance	$0	$0	$0	$20,464	$21,914
Additions from Purchase Accounting	21,914	0	21,914	'	'
Currency translation	-1,450	0	-1,450	'	'
Ending balance	$20,464	$0	$20,464	$20,464	$21,914

Goodwill_Intangibles_and_Purch4

Goodwill, Intangibles and Purchased Technology (Intangible Assets) (Details) (USD $)

1 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

BioVectra [Member]

Synacthen [Member]

Doral [Member]

Trademarks [Member]

Patents [Member]

Contracted Customer Relationships [Member]

Non-Contracted Customer Relationships [Member]

In Process R&D [Member]

Minimum [Member]

Maximum [Member]

Weighted Average [Member]

Synacthen [Member]

Minimum [Member]

Maximum [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Gross Book Value

$35,581,000

$33,186,000

$8,151,000

$58,000

$17,208,000

$10,164,000

$196,663,000

Accumulated Amortization

-3,055,000

-15,000

-1,578,000

-1,462,000

-5,212,000

Currency Translation

-2,395,000

-577,000

-3,000

-1,154,000

-661,000

Intangibles and other non current assets

30,131,000

191,500,000

7,574,000

40,000

14,476,000

8,041,000

191,451,000

Intangibles [Roll Forward]

Beginning balance

191,500,000

7,574,000

40,000

14,476,000

8,041,000

Intangibles resulting from the acquisition of BioVectra

35,581,000

Amortization expense

-3,055,000

-3,100,000

-800,000

-1,300,000

-300,000

-5,200,000

Currency translation

-2,395,000

Ending balance

30,131,000

191,500,000

7,574,000

40,000

14,476,000

8,041,000

191,451,000

Life of amortizable intangible asset

'8 years

'10 years

'9 years

'20 years

Years in development

'7 years

'8 years

Years of patent exclusivity

'11 years

'12 years

Amortization expense in 2014

3,200,000

9,800,000

Amortization expense in 2015

3,200,000

9,800,000

Amortization expense in 2016

3,100,000

9,800,000

Amortization expense in 2017

2,800,000

9,800,000

Amortization expense in 2018

2,600,000

9,800,000

Amortization expense thereafter

7,500,000

142,400,000

Amortization expense

3,055,000

3,100,000

800,000

1,300,000

300,000

5,200,000

Impairment of goodwill and intangibles

700,000

299,000

719,000

987,000

Agreed upon purchase price for the Purchased Technology

$700,000

Preferred_Stock_And_Shareholde2

Preferred Stock And Shareholders' Equity (Narrative) (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

70 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 28, 2012

10-May-12

29-May-09

Feb. 29, 2008

Apr. 30, 2008

31-May-11

Dec. 31, 2013

31-May-04

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Previous [Member]

As Amended [Member]

2006 Equity Incentive Award Plan [Member]

2004 Non-Employee Directors' Equity Incentive Plan [Member]

Restricted Stock Awards [Member]

Performance Shares [Member]

Restricted Stock Units [Member]

Restricted Stock and Restricted Stock Units [Member]

Common Stock [Member]

Stock Repurchase Program [Member]

Outside Of Stock Repurchase Program [Member]

Previous [Member]

As Amended [Member]

2006 Equity Incentive Award Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock, shares authorized

5,334,285

Stock repurchase program, number of shares authorized to be repurchased

7,000,000

5,000,000

6,500,000

7,000,000

Stock repurchased during period, value

$393,300,000

$53,100,000

$261,800,000

$363,000,000

$30,300,000

Stock repurchased during period, shares

23,100,000

960,000

6,759,861

16,961,661

6,200,000

Stock acquired, average cost per share

$17.01

$21.40

$4.93

Stock repurchase program, remaining number of shares authorized to be repurchased

5,292,793

Employee stock purchase plan, shares available for issuance, including previously issued

3,500,000

Employee stock purchase plan, maximum offering period in months

'27 months

'6 months

Employee stock purchase plan, eligibility requirements, hours worked per week minimum

'20 hours

Employee Stock Purchase Plan, eligibility requirements, months worked per calendar year minimum

'5 months

Employee stock purchase plan, maximum earnings withheld

15.00%

Employee stock purchase plan, purchase price per share, percentage of fair market value

85.00%

Issuance of common stock pursuant to employee stock purchase plan, shares

-137,472

-92,030

-90,650

-137,472

-92,030

-90,650

Vesting period, years

'4 years

Stock issued during period, share based compensation

207,250

Expiration period, years

'10 years

Granted

829,899

10,515

Stock options, increase of shares of common stock authorized for issuance

3,500,000

Share-based compensation arrangement by share-based payment award, number of shares authorized

9,750,000

Stock options granted following appointment as a Non-Employee Director

25,000

Stock options granted for continued service upon reappointment annually

15,000

Stock options granted to members of one or more committees of the board of directors

10,000

Stock options granted to chairs of one or more committees

7,500

Stock option grant, exercise price, percentage of fair market value

85.00%

100.00%

Common stock, shares authorized for grant

1,250,000

Shares of common stock reserved for issuance

2,570,483

Share-based compensation arrangement by share-based payment award, options, exercises in period, total intrinsic value

74,900,000

29,900,000

57,500,000

Issuance of common stock upon exercise of stock options

15,989,000

3,675,000

5,224,000

Shares granted

829,899

777,524

31,762

Expense related to the vesting of stock

14,600,000

1,800,000

163,000

1,600,000

9,000

Awards vested, total fair value

12,700,000

700,000

115,000

Unrecognized compensation cost

25,200,000

500,000

25,800,000

Unrecognized compensation cost, unvested stock options

$20,400,000

Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition in years

'2 years 2 months 1 day

Preferred_Stock_And_Shareholde3

Preferred Stock And Shareholders' Equity (Employee Stock Purchase Plan Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Purchase Plan Activity [Roll Forward]	'	'	'
Available at beginning of period	682,080	'	'
Purchases	-137,472	-92,030	-90,650
Shares added to the Plan	0	'	'
Available at end of period	544,608	682,080	'
Purchases, Weighted-Average Fair Value	$29.49	'	'

Preferred_Stock_And_Shareholde4

Preferred Stock And Shareholders' Equity (Valuation Assumptions) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Purchase Plan [Member]	'	'	'
Weighted average volatility	52.00%	110.00%	53.00%
Risk-free interest rate	0.07%	0.09%	0.08%
Expected term (in years)	'3 months	'3 months	'3 months
Expected dividend yield	2.40%	1.40%	0.00%
Stock Options [Member]	'	'	'
Volatility	71.00%	72.00%	61.00%
Forfeiture rate	4.05%	4.99%	7.61%
Expected term (in years)	'3 years 7 months 6 days	'3 years 7 months 2 days	'3 years 4 months 24 days
Expected dividend yield	2.60%	3.20%	0.00%
Stock Options [Member] \| Minimum [Member]	'	'	'
Risk-free interest rate	0.40%	0.30%	0.50%
Stock Options [Member] \| Maximum [Member]	'	'	'
Risk-free interest rate	0.80%	0.50%	2.40%

Preferred_Stock_And_Shareholde5

Preferred Stock And Shareholders' Equity (Summary Of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'
Outstanding at beginning of period	6,446,618	'	'
Granted	426,896	'	'
Exercised	-1,692,920	'	'
Forfeited or expired	-118,489	'	'
Outstanding at end of period	5,062,105	6,446,618	'
Options vested and expected to vest at end of period	4,993,859	'	'
Exercisable at end of period	3,442,547	'	'
Outstanding beginning of period, Weighted-Average Exercise Price	$16.52	'	'
Granted, weighted-average exercise price	$35.66	$36.16	$16.89
Exercised, weighted-average exercise price	$9.44	'	'
Forfeited or expired, weighted-average exercise price	$30.16	'	'
Outstanding end of period, weighted-average exercise price	$20.18	$16.52	'
Options vested and expected to vest at end of period, weighted-average exercise price	$19.99	'	'
Exercisable at end of period, weighted-average exercise price	$15.02	'	'
Outstanding at end of period, weighted-average remaining contractual term, years	'6 years 11 months 23 days	'	'
Options vested and expected to vest at end of period, weighted-average remaining contractual term, years	'6 years 11 months 16 days	'	'
Exercisable at end of period, weighted-average remaining contractual term, years	'6 years 4 months 17 days	'	'
Outstanding at end of period, aggregate intrinsic value	$173,920,567	'	'
Options vested and expected to vest at end of period, aggregate intrinsic value	172,493,803	'	'
Exercisable at end of period, aggregate intrinsic value	135,750,172	'	'
Restricted Stock Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'
Outstanding at beginning of period	0	'	'
Granted	10,515	'	'
Exercised	0	'	'
Forfeited or expired	0	'	'
Outstanding at end of period	10,515	'	'
Options vested and expected to vest at end of period	9,622	'	'
Exercisable at end of period	0	'	'
Outstanding beginning of period, Weighted-Average Exercise Price	$0	'	'
Granted, weighted-average exercise price	$51.69	'	'
Exercised, weighted-average exercise price	$0	'	'
Forfeited or expired, weighted-average exercise price	$0	'	'
Outstanding end of period, weighted-average exercise price	$0	'	'
Options vested and expected to vest at end of period, weighted-average exercise price	$0	'	'
Exercisable at end of period, weighted-average exercise price	$0	'	'
Outstanding at end of period, weighted-average remaining contractual term, years	'2 years 2 months 1 day	'	'
Options vested and expected to vest at end of period, weighted-average remaining contractual term, years	'2 years 1 month 13 days	'	'
Exercisable at end of period, weighted-average remaining contractual term, years	'0 years	'	'
Outstanding at end of period, aggregate intrinsic value	572,541.75	'	'
Options vested and expected to vest at end of period, aggregate intrinsic value	523,915.46	'	'
Exercisable at end of period, aggregate intrinsic value	$0	'	'

Preferred_Stock_And_Shareholde6

Preferred Stock And Shareholders' Equity (Restricted Stock Activity) (Details) (Restricted Stock Awards [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted Stock Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'	'	'
Non-vested shares at beginning of period	789,479	'	'
Granted	829,899	'	'
Vested	-205,181	'	'
Forfeited or expired	-51,033	'	'
Non-vested shares at end of period	1,363,164	789,479	'
Non-vested shares at beginning of period, Weighted-Average Fair Value	$26.42	'	'
Granted, Weighted-Average Fair Value	$34.14	$26.86	$27.28
Vested, Weighted-Average Fair Value	$26.50	'	'
Forfeited or expired, Weighted-Average Fair Value	$28.34	'	'
Non-vested shares at end of period, Weighted-Average Fair Value	$30.99	$26.42	'

Preferred_Stock_And_Shareholde7

Preferred Stock And Shareholders' Equity (Weighted Average Fair Value Of Equity Instruments) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock options	$35.66	$36.16	$16.89
ESPP [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Awards other than options	$29.49	$28.91	$14.98
Restricted Stock Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Awards other than options	$34.14	$26.86	$27.28
Restricted Stock Units [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock options	$51.69	'	'
Awards other than options	$51.69	$0	$0

Preferred_Stock_And_Shareholde8

Preferred Stock And Shareholders' Equity (Share-Based Compensation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based compensation expense	$28,753	$15,792	$7,326
Selling and marketing	'	'	'
Share-based compensation expense	10,897	5,360	4,236
General and administrative	'	'	'
Share-based compensation expense	12,302	7,467	1,884
Research and development	'	'	'
Share-based compensation expense	$5,554	$2,965	$1,206

Indemnifications_Commitments_A2

Indemnifications, Commitments And Contingencies (Narrative) (Details) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Jun. 30, 2011

Dec. 31, 2013

Jun. 11, 2013

Dec. 31, 2013

Jun. 11, 2013

Sep. 26, 2012

Oct. 04, 2012

Mar. 31, 2013

Dec. 31, 2013

building

Prior Owner of Acthar [Member]

Glenridge Pharmaceuticals, LLC [Member]

BioVectra [Member]

Synacthen [Member]

In re Questcor Securities Litigation [Member]

In re Questcor Shareholder Derivative Litigation [Member]

David Taban, et al. v. Questcor Pharmaceuticals, Inc [Member]

Hayward, California [Member]

Ellicott City, Maryland [Member]

Anaheim, California [Member]

principal

Maximum [Member]

lawsuit

sqft

Other Commitments [Line Items]

Deposit Assets

$77,000

Rent expense for facilities and equipment

1,200,000

1,000,000

Buildings leased

Lease revaluation term

'10 years

Typical lease terms for office equipment and automobile leases, years

'3 years

Rent expense for facilities, equipment and automobiles

4,000,000

Size of space (square feet)

30,000

15,600

7,900

Number of defendants

Number of plaintiffs

Damages sought

5,000,000

Period to supply pharmaceutical product

'10 years

'12 months

Total cash paid for acquisition of BioVectra

50,803,000

Current portion of contingent consideration

4,238,000

Changes in fair value of contingent consideration

6,429,000

Upfront consideration paid

60,000,000

Annual cash payments

25,000,000

Annual payments secured by a letter of credit

75,000,000

Total payment

300,000,000

Acquired intangibles, net

30,131,000

191,500,000

Contingent consideration estimate

140,100,000

Annual royalty, based on net sales, percentage

1.00%

Minimum level of net sales needed for royalty payments

10,000,000

Quarterly royalty, based on net sales, percentage

3.00%

Royalty expense

$30,400,000

$20,200,000

$8,500,000

Indemnifications_Commitments_A3

Indemnifications, Commitments And Contingencies (Future Minimum Payments) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases due 2014	$5,651
Operating Leases due 2015	4,173
Operating Leases due 2016	2,123
Operating Leases due 2017	1,085
Operating Leases due 2018	291
Thereafter	331
Total	$13,654

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
Income Taxes (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Undistributed earnings	$1,000,000	'	'
Deferred tax liability not recognized	1,281,000	1,223,000	1,274,000
Increase (decrease) in valuation allowance	-61,000	36,000	'
Research and development credits	68,000	92,000	'
Unrecognized tax benefits, income tax penalties and interest accrued	78,000	106,000	'
Unrecognized tax benefits, expected decrease as a result of settlement with IRS	500,000	'	'
Federal [Member]	'	'	'
Operating loss carryforwards	2,900,000	'	'
State [Member]	'	'	'
Operating loss carryforwards	15,300,000	'	'
California [Member]	'	'	'
Research and development credits	$100,000	'	'

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Before Income Taxes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal	$449,285	$297,230	$113,745
Foreign	-9,745	0	0
Income before income taxes	$439,540	$297,230	$113,745

Income_Taxes_Components_Of_the

Income Taxes (Components Of the Income Tax Expense) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Current federal income tax expense (benefit)	'	'	'	'	'	'	'	'	$158,914	$97,267	$38,575
Current state income tax expense (benefit)	'	'	'	'	'	'	'	'	1,615	2,047	475
Current foreign tax expense (benefit)	'	'	'	'	'	'	'	'	1,251	0	0
Current income tax expense (benefit), total	'	'	'	'	'	'	'	'	161,780	99,314	39,050
Deferred federal income tax expense (benefit)	'	'	'	'	'	'	'	'	-13,026	344	-4,782
Deferred state income tax expense (benefit)	'	'	'	'	'	'	'	'	-64	-103	-114
Deferred foreign income tax expense (benefit)	'	'	'	'	'	'	'	'	-1,759	0	0
Deferred income tax expense (benefit), total	'	'	'	'	'	'	'	'	-14,849	241	-4,896
Total income tax expense	$48,839	$45,668	$33,969	$18,455	$32,987	$27,836	$19,724	$19,008	$146,931	$99,555	$34,154

Income_Taxes_Reconciliation_Ta

Income Taxes (Reconciliation Tax Rate ) (Details)	12 Months Ended
Income Taxes (Reconciliation Tax Rate ) (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Tax at U.S. statutory rate	35.00%	35.00%	35.00%
State income taxes, net	0.40%	0.70%	0.20%
Change in valuation allowance	0.00%	0.00%	0.00%
Orphan drug tax credit	0.00%	0.00%	-2.10%
Foreign rate differential	0.70%	0.00%	0.00%
Other	-2.70%	-2.20%	-3.10%
Effective tax rate	33.40%	33.50%	30.00%

Income_Taxes_Significant_Compo

Income Taxes (Significant Components Of Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$1,879	$2,117
Research and development credits	68	92
Sales-related reserves	4,656	5,803
Stock-based compensation	12,575	8,006
Intangible asset	1,121	0
Other, net	12,240	2,219
Total deferred tax assets	32,539	18,237
Valuation allowance	-920	-981
Net deferred tax assets	31,619	17,256
Deferred tax liabilities:	'	'
Capital assets	-10,569	0
Net deferred taxes	$21,050	$17,256

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'
Balance at beginning of year	$1,223	$1,274
Increase / (decrease) of unrecognized tax benefits taken in prior years	377	-437
Increase of unrecognized tax benefits related to current year	-319	386
Balance at end of year	$1,281	$1,223

Defined_Contribution_Plan_Narr

Defined Contribution Plan (Narrative) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Postemployment Benefits [Abstract]	'	'	'
Maximum percentage of eligible compensation allowed for participating employees to contribute to their defined-contribution savings plan	60.00%	'	'
Defined-contribution savings plan, employer matching contribution	$1.50	$1	$0.30

Quarterly_Results_Of_Operation2

Quarterly Results Of Operations (Quarterly Financial Information ) (Details) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'		'		'		'		'		'		'		'		'	'	'
Total net sales	$242,881		$236,346		$184,573		$135,129		$160,533		$140,339		$112,452		$95,968		$798,929	$509,292	$218,169
Cost of sales (exclusive of amortization of purchased technology and IPR&D asset)	20,921		20,034		17,221		16,189		9,157		7,499		6,379		5,520		74,365	28,555	12,459
Income tax expense	48,839		45,668		33,969		18,455		32,987		27,836		19,724		19,008		146,931	99,555	34,154
Net income	89,981		94,441		69,123		39,064		61,940		55,687		41,505		38,543		292,609	197,675	79,591
Comprehensive Income	$88,430		$95,372		$67,644		$37,870		$61,926		$55,700		$41,491		$38,634		$289,316	$197,751	$79,532
Net income per share applicable to common shareholders:	'		'		'		'		'		'		'		'		'	'	'
Basic (in dollars per share)	$1.51	[1]	$1.60	[1]	$1.17	[1]	$0.68	[1]	$1.07	[1]	$0.95	[1]	$0.68	[1]	$0.61	[1]	$4.99	$3.28	$1.27
Diluted (in dollars per share)	$1.44	[1]	$1.52	[1]	$1.12	[1]	$0.65	[1]	$1.03	[1]	$0.91	[1]	$0.65	[1]	$0.58	[1]	$4.76	$3.14	$1.21
Dividends declared per common share	$0.60		$0		$0.25		$0.25		$0.20		$0.20		$0		$0		$1.10	$0.40	$0

[1]	Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Schedule_II_Valuation_And_Qual1

Schedule II Valuation And Qualifying Accounts (Valuation And Qualifying Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reserves for uncollectible accounts	'	'	'
Balance at Beginning of Period	$0	$0	$25
Additions/ (Deductions) Charged to Income	475	0	0
Deductions and Write-Offs	0	0	25
Balance at End of Period	475	0	0
Reserves for obsolete and excess inventories	'	'	'
Balance at Beginning of Period	52	0	158
Additions/ (Deductions) Charged to Income	1,329	52	0
Deductions and Write-Offs	52	0	158
Balance at End of Period	1,329	52	0
Sales-related reserves	'	'	'
Balance at Beginning of Period	37,376	34,119	21,511
Additions/ (Deductions) Charged to Income	52,129	64,707	50,658
Deductions and Write-Offs	54,135	61,450	38,050
Balance at End of Period	$35,370	$37,376	$34,119